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ABSTRACT OF DISSERTATION 
 
 
EFFECTS OF ADIPOCYTE DEFICIENCY OF ANGIOTENSIN TYPE 1A 
RECEPTORS IN MODELS OF OBESITY AND HYPERCHOLESTEROLEMIA 
 
Adipocytes express angiotensin II (AngII) receptors; however the direct 
effects of AngII at the adipocyte remain unclear.  Knockout mouse models of 
renin-angiotensin system components exhibit reduced body weight, reduced 
adiposity, improved glucose tolerance, and improved blood pressure when fed 
high fat diets, which may be due to reduced action of AngII through the AT1aR in 
adipocytes.  Additionally, hypercholesterolemic AT1aR deficient mice are 
protected from AngII-induced increases in atherosclerosis and abdominal aortic 
aneurysm (AAA) formation.  We hypothesized that deficiency of AT1aR in 
adipocytes would reduce the development of obesity, obesity-induced disorders, 
and vascular diseases.  To test this hypothesis, we created a mouse model of 
adipocyte AT1aR deficiency using the Cre/LoxP system.  Adipocyte-AT1aR 
deficiency confers no protection from the development of obesity or obesity-
associated parameters.  However, low fat fed adipocyte-AT1aR deficient mice 
exhibit remarkable adipocyte hypertrophy and reductions in adipocyte 
differentiation.  These results demonstrate that AngII is a stimulus for adipocyte 
 
 
differentiation and adipocyte hypertrophy alone is insufficient to initiate obesity-
associated disorders.  In hypercholesterolemic mice, adipocyte AT1aR deficiency 
conferred no protection from diet or AngII-induced vascular diseases.  Overall 
these studies suggest the primary role of adipocyte AT1aRs is to promote 
adipocyte differentiation and the development of small adipocytes. 
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SECTION I. BACKGROUND 
1.1.1 The renin-angiotensin system (RAS)  
 The renin-angiotensin system (RAS) is an endocrine system that regulates 
blood pressure through the actions of angiotensin peptides acting through 
various angiotensin receptors.  Angiotensin peptides are cleavage products of a 
precursor protein, angiotensinogen (AGT).  AGT is a glycosylated protein 
secreted primarily from liver, though important secondary sources include 
adipose and brain tissues.  The aspartyl protease renin is produced in 
juxtaglomerular cells and cleaves 10 amino acids from the N-terminus of AGT to 
form the inactive peptide, angiotensin I (AngI).  Subsequent cleavage of two 
amino acids from the C-terminus of AngI by the metalloproteinase angiotensin 
converting enzyme (ACE) produces the predominant peptide of this system, 
angiotensin II (AngII) (Figures 1.1 and 1.2A).  Catabolism of AngII by 
aminopeptidases produces smaller angiotensin peptides such as angiotensin III 
or IV and importantly, the C-terminal phenylalanine can be removed by 
angiotensin converting enzyme 2 (ACE2) to form angiotensin-(1-7) (Ang(1-7)), 
which acts through the Mas receptor to oppose the effects of AngII. 
1.1.2 Angiotensin receptors 
1.1.2.1 Types of angiotensin receptors and their tissue distributions 
 In humans, the actions of AngII are mediated by two G-protein coupled  
receptors, angiotensin type 1 (AT1R) and angiotensin type 2 (AT2R) receptors.  
Rodents, however, have two subtypes of the AT1R, the AT1aR and AT1bR, 
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which are 94% homologous (Hein 1998).  Prior to the identification of the rodent 
subtypes, the human AT1R was found to share 95% homology with rat AT1R 
(Bergsma 1992}.  The AT1R in humans and the AT1aR in rodents are expressed 
with similar tissue distributions, including kidney, adrenal gland, vasculature, 
epicardium, liver, lung, circumventricular organs of the brain, ovaries/testes, and 
adipose tissues (44, 70).  In contrast, expression of AT1bR is limited to adrenal 
gland, anterior pituitary gland, testes, hypothalamus, and resistance vessels (36, 
52, 294).  Knockout models provide another indication that the rodent AT1aR is 
most similar to the AT1R of humans because AT1aR deficient mice demonstrate 
reduced blood pressure in most studies, consistent with pharmacological 
blockade of AT1R in humans, whereas AT1bR deficient mice do not demonstrate 
this pathology (52, 119).  AT1bRs have been implicated in contractile 
responses to AngII in mesenteric resistance vessels of mice, supporting tissue-
specific roles for AT1bRs (294).  The other AngII receptor, AT2R, is 34% 
homologous compared to AT1R.  Although AT2R is highly expressed during fetal 
development (98), more restricted expression in adults has been demonstrated in 
brain, adrenal gland, liver, kidney, myocardium, endothelium, uterus/ovary, and 
adipose with upregulation of AT2R during some pathological states (61, 269).  
1.1.2.2 Structure and signaling of angiotensin receptors 
All AngII receptors are classic seven transmembrane G-protein coupled 
receptors.  The AT1R comprises 359 amino acids (Figure 1.2B) and has a 
molecular mass of 41 kDa, though glycosylation at four extracellular residues 
increases the mass to 65 kDa (124).  Binding of AngII to AT1R requires 
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interactions between the tyrosine residue of AngII and the Asn111 residue of the 
third transmembrane domain as well as between the phenylalanine of AngII and 
His256 of the sixth transmembrane domain (186).  These transmembrane 
residues of the AT1R are part of a transmembrane binding pocket present in 
several GPCRs and the aromaticity of the Tyr and Phe residues of AngII may 
facilitate these interactions.  Multiple G protein-dependent signaling pathways 
can be activated by AngII through the AT1R (Figure 1.3A).  The AT1R initially 
couples to Gq/11 to activate phospholipase C-β (PLC- β), an enzyme that cleaves 
phosphatidylinositol (PIP2) to diacylglycerol and inositol triphosphate (IP3).  IP3 
then stimulates intracellular calcium (Ca2+) release, which is a key initiating event 
in contraction of muscle cells.  While this pathway is well-characterized, AT1R 
signaling pathways vary by cell type.  In vascular smooth muscle cells, AngII-
stimulated AT1Rs can activate phospholipase C-γ through tyrosine 
phosphorylation by intermediate tyrosine kinases, as the AT1R has no tyrosine 
kinase activity of its own; tyrosine kinases activated by AT1Rs include c-Src, 
focal adhesion kinase,  Ca2+ -dependent kinases, Janus kinases, and receptor 
tyrosine kinases (24, 67, 263).  Activation of tyrosine kinases may play a role in 
transactivation of the epidermal growth factor receptor through AngII-induced 
phosphorylation of ADAM17, an enzyme that cleaves epidermal growth factor 
from its heparin binding (110, 168).  AngII may also transactivate other growth 
factor receptors, such as platelet-derived growth factor or insulin-like growth 
factor receptors, though these mechanisms are less clear (72, 250).  In adrenal, 
liver, kidney, and pituitary gland cells AT1R can activate Gi/o proteins that inhibit 
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adenylyl cyclase and in rat portal vein myocytes AT1R can activate G12/13 
proteins to activate L-type calcium channels (67, 156). 
 The AT1R can also activate signaling pathways independent of G-protein 
coupling (Figure 1.3B).  Interestingly, the AT1R is subject to biased agonism, 
whereby these non-G-protein signaling pathways can be preferentially activated 
by analogues of AngII such as [SII] (AngII with substituted 
Sarcosine1,Isoleucine4, Isoleucine8) (11, 139).  These G-protein independent 
pathways involve the recruitment of β-arrestin as a result of phosphorylation by 
GPCR kinases (GRKs) and result in receptor internalization and activation of 
Extracellular signal regulated kinases 1/2 (ERK 1/2).  In addition to ligand-
activated signaling through G-protein coupled or G-protein independent 
pathways, AT1Rs are also capable of ligand-independent activation, such as by 
mechanical stress.  Following up on initial reports that AT1R antagonists could 
only partially attenuate mechanical-stress induced activation (282), more recent 
studies have confirmed that AT1Rs undergo conformational changes during 
mechanical stress that initiate ERK activation and result in cardiac hypertrophy 
independent of AngII activation of the receptor, and administration of 
candesartan reduces these effects, suggesting the conformation of candesartan-
bound AT1Rs is unable to respond to mechanical stress (166, 298).  
The AT2R is 34% homologous with the AT1R and some of the structural 
differences include additional cysteine residues in the N-terminal region and the 
third extracellular loop which form stabilizing disulfide bonds in the AT1R but are 
not present in the AT2R (190).   The AT2R binds to Giα2 or Giα3 (292) and 
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activates various phosphatases, including serine/phosphatase 2A (PP2A) and 
MAPK phosphatase (MKP-1), through which it can functionally antagonize 
signaling pathways activated by the AT1R (67).  In cardiac myocytes, AT2R 
activation can result in the release of arachidonic acid via stimulation of 
phospholipase A2 (152) and it has also been reported in Ob1771 adipocytes that 
activation of the receptor mediates the release of prostacyclin (PGI2), a 
downstream product of arachidonic acid metabolism (61).  
1.1.2.3  Regulation of angiotensin receptor function at the plasma membrane 
 Similar to many plasma membrane receptors, GPCRs undergo 
internalization and subsequent degradation or recycling, which in the case of 
GPCRs is agonist-dependent.  In the case of AT1Rs, internalization is 
downstream of β-arrestin signaling pathways which are G-protein independent 
but requires receptor phosphorylation at the C-terminal tail by G-protein coupled 
receptor kinases (GRKs) (192, 260).  In vascular smooth muscle cells, AT1Rs 
are associated with caveolae within 5 minutes of AngII stimulation and data 
suggest AT1R internalization may in part be due to caveolae-mediated 
endocytosis (118).  Interestingly, the AT2R is a rare example of a GPCR that 
does not undergo receptor internalization (265).   
 In recent years, the possibility of GCPR dimerization or oligomerization 
has surfaced as a potential modulator of receptor signaling and several studies 
suggest that AT1R signaling may be affected by homo- or hetero-oligomerization 
(252).  Oligomerization may play a role in directing the propensity of AT1R for G-
protein activation or ERK activation (106).  Interestingly, inhibition of one AT1R 
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within an homo-oligomer is sufficient to inhibit signaling of other receptors within 
the complex, providing more evidence that receptor conformations can be altered 
by formation of oligomers (136).  Aggregation of AT1Rs can also occur at the cell 
surface in response to environmental stimuli, including oxidative stress.  Image 
correlation spectroscopy (ICS) has revealed that AT1R oligomerization at the cell 
surface increases in response to incubation with AngII, with further increases 
upon treatment with H2O2, and oligomerization is associated with enhanced 
AT1R-induced increases in intracellular Ca2+ (249).  Potential pathological 
relevance of AT1R homodimerization was demonstrated in hypertensive patients 
with increased atherogenic risk factors who had increased levels of crosslinked 
AT1R homodimers in monocytes capable of enhanced signaling (2).  Potentiation 
of AT1R signaling can also occur through heterodimerization with other 
receptors, such as the cannabinoid type 1 (CB1R), β-adrenergic (β-AR), and 
bradykinin 2 (B2R) receptors (3, 20, 219).  AT1R/B2R heterodimers have been 
implicated in the development of preeclampsia with studies demonstrating 
increased levels of heterodimers that protect AT1R from oxidative stress-induced 
inactivation (1).  Oligomerization and heterodimerization present interesting 
means through which AT1R signaling can be augmented, especially in response 
to oxidative stress, with pathophysiological consequences and may lead to 
additional therapeutic strategies. 
 Another mode of regulation of AT1R activity is through its distribution in 
membrane microdomains within the plasma membrane.  A recent study 
fluorescently labeled lipid raft and non-raft domains and examined the 
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redistribution and signaling capabilities of wild-type and mutant receptors upon 
ligand-binding.  Under resting conditions, AT1aRs were found to localize in lipid 
raft domains, however AngII stimulation caused movement to non-raft domains 
through Gq protein activation in HEK-293 cells (18).   
 Regulatory proteins can also bind to AT1R at the cell surface to direct 
AT1aR internalization, such as angiotensin type 1 receptor-associated protein 
(ATRAP) and the rat type 1 angiotensin II receptor associated protein 1 (ARAP1).  
In mouse cardiomyocytes, ATRAP binds to an intracellular region of the receptor 
and remains with the receptor as it is internalized after stimulation with AngII and 
co-expression studies indicate that ATRAP plays an active role in decreasing 
AT1aRs at the cell surface.(255)  ARAP1, on the other hand, binds to a similar 
region of the AT1aR but serves to enhance receptor recycling to the cell surface 
in HEK-293 cells (99).  Dysregulation of these regulatory proteins in disease 
states may serve to potentiate AT1aR signaling and may present new 
therapeutic targets. 
1.1.2.4 Regulation of angiotensin receptor expression 
 Regulation of AT1aR expression has been examined primarily in the 
context of vascular smooth muscle cells (VSMCs).  Negative regulators of AT1R 
expression include AngII itself, estrogen, reactive oxygen species (ROS), high-
density lipoprotein (HDL), and TGF-β1 (149, 180, 184, 272, 293).  Pathogenic 
stimuli such as hypercholesterolemia and high salt diets are positive regulators of 
AT1R expression, which may contribute to the role of the RAS in diseases such 
as atherosclerosis or hypertension (181-182, 185). 
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 Posttransciptional regulation of AT1R mRNA can occur through 
stabilization or destabilization of AT1R mRNA.  The AngII-mediated decay of 
AT1R mRNA is dependent on the AUUUUA hexamer within the 3’ UTR which 
results in a stem-loop structure required for the recruitment of the exosome 
complex containing mRNA binding proteins that accelerate mRNA decay (23).  
Proteins such as nuclear riboprotein S1-1 and p100 protein stabilize while 
phosphorylated calreticulin destabilizes AT1R mRNA (173-174, 196).  
Interestingly, insulin has also been identified as having AT1R mRNA-stabilizing 
properties and enhanced AT1R expression induced by hyperinsulinemia may 
contribute to the role of the RAS in the metabolic syndrome (183). 
1.2.1 Adipose RAS 
 Components of the RAS required to synthesize and respond to AngII are 
expressed in adipocytes.  AGT expression was first discovered in peri-aortic 
adipose tissue and subsequently confirmed in other adipose depots, including 
both white and brown adipose tissue of rodents (39, 46, 94, 226) and white 
adipocytes of humans (76).  In fact, adipocytes are an important extra-hepatic 
source of angiotensinogen, with 68% of the mRNA abundance observed in liver 
(154).  The expression and activity of renin and ACE in adipocytes is less clear.  
While some groups have failed to detect renin mRNA transcripts in brown or 
white adipocytes (76, 235), others have detected transcripts (97, 137) and renin 
activity (230, 235).  Similarly, reports of ACE expression and activity range from 
undetectable (59) to low (131, 198).  The fact that AngII is detectable in the 
media of cultured adipocytes after 6 days of media changes suggests that while 
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renin and ACE activity may be low in these cells, it is sufficient for processing 
AGT to measurable levels of AngII (230).  In whole adipose tissue in vivo, the 
ability of other cell types such as preadipocytes, endothelial cells, and 
macrophages to produce these components may contribute to the local 
production of AngII.  Additionally, other RAS components, such as prorenin 
receptor and ACE2, are located in adipocytes and may regulate AngII production 
(89, 100). 
1.2.2 Adipose angiotensin receptors 
 Adipocytes have the ability to respond to either locally or systemically 
produced AngII because they express angiotensin receptors.  Initial ligand-
binding assays by Crandall, et al. and Cassis, et al. demonstrated the presence 
of AT1R on rat adipocytes using the selective AT1R antagonist, losartan, to 
successfully compete for AngII binding (44, 59).  Crandall, et al. observed AngII 
binding adipose AT1Rs with an approximate affinity of 1 nM and receptor density 
was greatest in epididymal, followed by retroperitoneal and mesenteric adipose 
depots when corrected for differences in cell volume (59).  Cassis, et al. similarly 
observed AT1R affinity ranging from 0.3-0.6 nM with epididymal fat containing 
the greatest number of receptor sites and interscapular brown adipose containing 
the least (44).  Both groups found that the selective AT2R antagonist, PD123319, 
was unable to effectively compete radiolabelled AngII binding, suggesting low 
expression levels of this receptor.  Other groups have confirmed the expression 
of AT1Rs with low or undetectable levels of AT2Rs in adipocytes derived from 
rodents and humans (76, 97, 198).  However, several groups have reported 
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AT2R-mediated effects of AngII on adipocytes using AT2R antagonists, so the 
functional relevance of AT2Rs cannot be ignored simply due to low expression 
levels (61, 130).  Expression of AT1bR was not detectable in adipose tissue (36). 
1.2.2.1 Regulation of adipocyte angiotensin receptors during differentiation 
 Expression levels of the AngII receptors change throughout the process of 
preadipocyte conversion to mature adipocytes, though there is controversy 
regarding the nature of these changes.  One group has shown that AT1aR 
protein levels remain strongly expressed throughout the course of 3T3-L1 
(murine embryonic fibroblast cell line capable differentiating to mature 
adipocytes) adipocyte differentiation while AT2R expression is lost after 12 days 
of differentiation (159).  Similarly, our lab demonstrated that AT1aR mRNA 
abundance increased significantly after 5 days of differentiation of 3T3-L1 
adipocytes and remained elevated through 10 days (100).  In studies of human 
preadipocytes differentiated to mature adipocytes, results show transient AT2R 
expression with either low levels of AT1R (163, 284) or increased AT1R as cells 
became adipocytes (122). At least one study has shown increased protein 
expression of AT2R with differentiation of human preadipocytes, and 
interestingly, in this study AT1R mRNA abundance decreased throughout 
differentiation even though the protein levels were unchanged, suggesting 
reduced mRNA stability and that mRNA abundance may not be a reliable 
indicator of protein expression (228).  However there is widespread controversy 
regarding the specificity of the antibodies of AT1Rs used in these studies for 
western blot analyses (212).  Despite a few instances to the contrary, most 
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groups agree that the expression of RAS components to produce AngII are 
increased with adipocyte differentiation (122, 163), though the regulation of 
angiotensin receptors is more difficult to ascertain.  Technical difficulties in 
measuring angiotensin receptors (e.g., specificity of antibodies), the species of 
adipocytes under study, or differences in expression levels resulting from 
experimental conditions (i.e., components included in cell culture media, duration 
of experiments, frequency of media changes, cellular production of AngII, etc) 
may contribute to divergence in AngII receptor subtypes on adipocytes.   
1.2.2.2 Regulation of adipose angiotensin receptors with obesity 
 Changes in gene and protein expression during adipocyte differentiation in 
vitro may or may not reflect changes in vivo during states of over-nutrition, as the 
relative contributions of adipogenesis and adipocyte hypertrophy to the obesity 
phenotype are still unclear (15, 60).  Early characterizations of AngII receptor 
expression in lean and obese Zucker rats revealed reductions in AT1R 
expression in liver but not in adipose depots (44).  Another study using neonatal 
monosodium glutamate (MSG) injection in rats as a model of adult-onset 
adipocyte hypertrophy and insulin resistance demonstrated that AngII-AT1R 
binding was decreased significantly with obesity although protein expression 
increased markedly (199).  While decreased ligand binding and increased protein 
levels may suggest a defect in receptor binding or internalization, few studies 
have followed up on these findings.  In humans, a study comparing normal and 
overweight patients observed no differences in AT1R mRNA abundance between 
the different weight groups, but higher AT1R mRNA levels in visceral compared 
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to subcutaneous adipose tissue (91).  Interestingly, another study examining 
AT1R expression among normotensive lean, obese normotensive, and obese 
hypertensive patients found that AT1R expression was similar in normotensive 
groups regardless of weight but was significantly increased in subcutaneous 
adipose of obese hypertensives (79).  This association between adipose AT1R 
expression and hypertension could reflect a predisposition of persons with 
increased AT1R in adipose to become hypertensive or an upregulation of 
adipose AT1R in response to hypertension, and determining whether AT1R 
upregulation is a cause or consequence could have important implications in 
identifying at-risk populations or treating obesity-hypertension. 
1.2.2.3 Regulation of adipose angiotensin receptors with age 
 Another important factor that may modulate adipose AT1R expression is 
the process of aging, especially because aging is associated with increased 
adiposity (256).  One study demonstrated that adipose AT1R mRNA levels 
decreased significantly between 4 and 12 weeks of age in male Wistar rats (6).  
These data conflicts with a recent study demonstrating that AT1R mRNA 
abundance was similar between rats aged 9, 12, or 20 weeks but was markedly 
increased by 26 weeks of age (147).  Interestingly, in this study protein levels of 
AT1R were not reflective of the mRNA abundance but were elevated after 12 
weeks of age and maintained through 26 weeks of age.  
1.2.2.4 Regulation of adipose angiotensin receptors by AngII 
 AT1R expression is downregulated in response to AngII incubation in 
VSMCs and in fact, most GPCRs exhibit reduced expression in response to 
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ligand-binding as a mechanism of self-regulation (149).  In adipose tissue, 
however, studies from our laboratory have indicated the opposite, that AngII 
increased AT1aR expression (154).  In this study, AT1aR mRNA levels were 
elevated in epididymal adipose of AT2R deficient mice fed standard mouse 
(chow) diet; however this increase was blocked by losartan.  These data indicate 
that deficiency of AT2Rs per se did not change AT1aR expression rather that 
enhanced AT1aR signaling in the absence of AT2Rs resulted in increased 
AT1aR mRNA expression.  Moreover, infusion of AngII markedly increased the 
expression of AT1aR mRNA in adipose tissue but not in liver, suggesting an 
adipose-specific positive feedback loop wherein AngII increases the expression 
of its own receptor.  While adipose up-regulation by AngII may result from AngII 
actions at adipocyte AT1aRs, this study used whole adipose tissue lysates to 
isolate mRNA and it is possible that other cell types within adipose tissue 
contributed to this effect.  In the setting of obesity, where the systemic RAS is 
thought to be elevated (57, 268), this positive feedback loop may be of particular 
importance and result in further elaboration of AngII’s effects on adipocytes. 
1.3 Evidence for a role of AngII in (patho)physiologic adipose tissue growth and 
function 
1.3.1.1 The process of adipocyte differentiation 
 Adipocyte differentiation comprises two distinct phases (Figure 1.4), the 
first is the commitment to the adipocyte lineage wherein mesenchymal stem cells 
(MSCs) become preadipocytes and the second is the terminal differentiation of a 
preadipocyte into a mature adipocyte (60).  In order for the commitment phase to 
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progress, inhibitory Wnt and TGF-β signaling pathways must be interrupted and 
stimulatory pathways involving zinc-finger protein 423 (ZFP423) and TCF7-like 1 
(TCFL1) transcription factors must be turned on.  Terminal differentiation begins 
with exogenous adipogenic stimuli that induce transient upregulation of 
CAAT/enhancer binding proteins (C/EBPβ and δ) which then induce PPARγ 
expression, which acts as a master regulator of differentiation through 
coordination with C/EBPα (280).  PPARγ is a nuclear receptor activated by 
polyunsaturated fatty acids and their derivatives that translocates to the nucleus, 
heterodimerizes with retinoid X receptor (RXR), and binds PPAR response 
elements (PPREs) in the DNA to recruit other co-activators to several target 
genes.  PPARγ and C/EBPα target genes include those for glycerophosphate 
dehydrogenase, fatty acid synthase, acetyl CoA carboxylase, malic enzyme, 
glucose transporters, insulin receptor, and fatty acid binding proteins (218).  
Other transcription factors involved in adipocyte differentiation include Krox20, 
Kruppel-like factors, Stat5A, and sterol-regulatory element-binding protein 
(SREBP)-1c (237).  In fact, adipocyte determination and differentiation-
dependent factor 1 (ADD1)/SREBP1 is another prominent regulator of 
differentiation, as dominant negative ADD1/SREBP1 attenuated differentiation of 
3T3-L1 cells (140).  Adipocyte differentiation can be inhibited by several growth 
factors, including FGF, PDGF, and EGF (including the membrane protein pref-1 
which contains EGF-like repeats), which act by stimulating MAPKs that 
phosphorylate and inactivate PPARγ (108, 239).  Several other hormones and 
growth factors act as adipogenic stimuli, however, and traditional differentiation 
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cocktails used in vitro contain insulin, dexamethasone (glucocorticoid), insulin-
like growth factor (IGF-1; present in fetal calf serum), isobutyl-1-methylxanthine 
(IMBX; cAMP-elevating agent), and more recently, a PPARγ ligand (107).   
 Adipocyte differentiation can be regulated by nutritional status.  Recent 
studies suggest that adipogenesis is inhibited in the setting of obesity (101, 116, 
197).  Specifically, lipid accumulation in differentiated human preadipocytes is 
inversely correlated to the subjects’ BMI as well as the size of adipocytes 
obtained from collagenase digestion (116).  Follow-up studies indicate that the 
mechanisms involved may include sustained inhibitory canonical WNT signaling 
pathways (101) or epigenetic changes resulting from hypertrophy-induced 
hypoxia (141).  Correspondingly, the numbers of adipocyte precursor cells in 
adipose tissue increase 270% with high fat feeding, supporting the conclusion 
that adipocyte differentiation is impaired, not the availability of precursor cells 
(155).  This suppression of adipocyte differentiation causes the remaining 
adipocytes to accumulate more lipid, thus contributing to adipocyte hypertrophy 
and its consequences, such as insulin resistance (13-14).  While these results 
provide interesting new insights into mechanisms of adipocyte hypertrophy, they 
are seemingly incongruent with other reports of increased adipocyte cell numbers 
in obese subjects (80, 143, 243), demonstrating that more research is necessary 
to understand the dynamics of adipogenesis in obesity.  Conversely, in the 
setting of nutrient deprivation, adipocyte differentiation may be enhanced.  
Calorie-restriction in rats for 2 or 25 months upregulates adipogenic markers, 
such as PPARγ, C/EBPα, and adiponectin and consequently adipocyte size was 
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reduced in these rats (295).  Other studies indicate that calorie-restriction of 3T3-
L1 cells causes the cells to revert to a proliferative state (213) which may or may 
not be conducive to adipocyte differentiation, again indicating the need for further 
research into these mechanisms of adipogenesis. 
1.3.1.2 Role of AngII in adipocyte differentiation 
There are several methods that have been used to study the process of 
adipocyte differentiation, including preadipocyte differentiation ex vivo, clonal 
preadipocyte cell lines capable of adipocyte differentiation, isolated primary 
adipocytes, or adipose tissue explants.  In the case of the RAS, these methods 
could be employed in the absence or presence of AngII and/or inhibitors of the 
RAS such as ACE inhibitors or angiotensin receptor blockers (ARBs).  One 
caveat, however, regarding the use of ARBs to study adipose tissue 
development is that some ARBs have been found to stimulate PPARγ, 
independently of AT1R blockade (22, 216, 231).  Two independent reports were 
published in 2004 that certain ARBs have PPARγ-agonizing properties 
independent of AT1R signaling (22, 231), which has been confirmed by 
subsequent studies in AT1aR-/- mice (216).  Telmisartan, irbesartan and 
candesartan consistently exert PPARγ-agonism while eprosartan, valsartan, and 
losartan have little or no ability to do so (13, 22, 54, 78, 86, 123, 231, 245, 296).  
At least one study, however, has identified the EXP3179 metabolite of losartan 
as a partial PPARγ agonist (232).  These properties of ARBs must be considered 
when interpreting investigations of the role of AngII or the AT1R in the process of 
adipocyte differentiation. 
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Few studies have examined the effects of AngII on the initial commitment 
step in which MSCs commit to the adipocyte lineage (Table 1.1).  One group 
incubated commercially available human mesenchymal stem cells with 3 cycles 
of adipocyte induction medium for 3 days followed by 3 days of adipocyte 
maintenance medium, including incubation with AngII alone or in combination 
with valsartan or PD123319 throughout the 18-day period and found that AngII 
decreased PPARγ, FAS, and lipid accumulation (163).  This anti-adipogenic 
effect was mediated through the AT2R, as valsartan further reduced the levels of 
PPARγ and FAS, indicating a pro-adipogenic effect of AngII through the AT1R. It 
is difficult, however, to determine if AngII influenced the initial commitment step 
or the terminal differentiation step because the treatments were maintained 
through the entire differentiation period.  In addition to influencing commitment to 
preadipocytes, AngII may also affect preadipocyte proliferation as it has been 
shown that AngII increases human preadipocyte proliferation through AT1R-
mediated increases in cyclin D expression (58).  AngII has also been reported to 
increase mature adipocyte cell numbers through the AT1R in serum-free 
conditions by increasing cell division, however it is unclear whether these results 
are relevant in vivo (225). 
Several studies have used preadipocytes isolated from the stromal 
vascular fraction of whole adipose tissue digested with collagenase, with some 
investigators reporting an anti-adipogenic effect of AngII (85, 122, 229)(Table 
1.1).  Of these studies, only Janke, et al. determined the role of AT1R versus 
AT2R in their observed effects, demonstrating that irbesartan administration in 
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the absence of exogenous AngII increased lipid accumulation while the AT2R 
antagonist had no effect (122).  However, as described above, irbesartan has 
AT1R-independent effects, complicating interpretation of these data.  Mouse 
fibroblast-like embryonic cell lines (Ob1771, 3T3-L1) have been valuable tools 
employed to study AngII’s role in adipocyte differentiation because they offer 
consistency in differentiation that is difficult to achieve from human-derived 
samples. However, these cell lines do not allow investigators to define the 
contributions of preadipocytes derived from different regional locations.  One of 
the first studies in this field found that AngII reduced adipocyte differentiation in 
OB1771 cells through the AT2R (61).  However, these results are also 
controversial because others found that exogenous (130) and endogenous (114) 
AngII increases lipid accumulation and markers of adipocyte differentiation.  In 
these studies both AT1R and AT2R antagonists reduced FAS and GPDH 
enzyme activities (130) or lipid accumulation (114).  Changes in adipocyte size 
and markers of adipocyte differentiation have also been studied in vivo, and 
these will be discussed later in terms of the role of AngII in the regulation of body 
weight. 
1.3.2.1 The pathophysiology of obesity 
The World Health Organization classifies people as obese with a body 
mass index (BMI) greater than 30 and overweight with a BMI of 25-29.9.  The 
latest data from the National Health and Nutrition Examination Survey in 2009-
2010 indicated that 35.7% of adults and approximately 17% of children 
nationwide are obese (187).  As recently as 1990, no state had a prevalence of 
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obesity greater than 15%, whereas in 2010 all states had obesity rates above 
20%, including 36 states above 25%, indicating the recent dramatic increases in 
obesity (187).  Obesity is a component of the metabolic syndrome, which is a 
cluster of risk factors that greatly increase the risk for cardiovascular disease and 
includes elevated waist circumference, blood pressure, fasting blood glucose, 
triglycerides, and reduced HDL (8).  Visceral obesity is the central component of 
the metabolic syndrome and is independently associated with each of the other 
factors (42).  Despite the strong associations between obesity and disease, 
about 15% of obese individuals are unaffected by obesity-associated disorders 
and manage to possess “metabolically healthy” adipose tissue, which is thought 
to be due to a high number of small (non-hypertrophied, non-hypoxic, or non-
inflamed) adipocytes (26).   
  While caloric intake in excess of energy requirements is the basis of 
obesity, it is a multi-factorial disease state that can be influenced by various 
genetic and environmental factors, including physical activity, regulation of 
satiety, addictive eating behaviors, hormonal imbalance, fetal programming, or 
even disturbances in intestinal microbiota.    Regardless of the causes of obesity, 
changes in adipose tissue growth, function, and remodeling dictate whether an 
obese individual develops obesity-associated disorders.  During the development 
of obesity, excess caloric intake results in increases in adipocyte size 
(hypertrophy), however as discussed previously, the contributions of precursor 
recruitment, commitment, proliferation, and differentiation are still under 
investigation (248).  Obesity is associated with increased macrophage infiltration 
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into adipose tissue (277) resulting from inappropriate adipose tissue remodelling 
to accommodate larger adipocytes (248).  Adipose tissue inflammation combined 
with ectopic lipid accumulation in non-adipose tissues connect obesity with other 
components of the metabolic syndrome to increase risk of cardiovascular 
disease (170).   
1.3.2.2 Genetic evidence for a role of AngII in the development of obesity  
 Polymorphisms have been identified in the genes for AGT, ACE, and 
AT1R that result in either reduced or increased functions of these proteins, with 
possible implications in the development of obesity and related disorders.  Three 
commonly studied mutations in the RAS include M235T AGT mutation, which 
results in higher plasma AGT levels (126), the A1166C AT1R mutation, which 
increases responsiveness of the AT1R (27), and the insertion/deletion (I/D) ACE 
mutation, in which D/D individuals have double the plasma ACE activity of I/I 
individuals (214).  The Olivetti Prospective Heart Study of 959 Italian men 
examined associations of these three mutations with BMI, body fat distribution, 
and obesity-associated hypertension (246).  This study found no association 
between the AGT or AT1R mutations with any of these parameters, however 
individuals with the D/D genotype in the ACE gene were significantly more likely 
to be overweight and have abdominal obesity.  Other studies have also found 
significant associations between the D allele and increased BMI (275) and 
individuals with at least one D allele in the ACE gene were more likely to have at 
least one of the following; obesity, hypertension, hyperlipidemia, or diabetes 
mellitus (266).  However, in the Health Aging and Body Composition Cohort 
21 
 
Study, the I/I genotype of the ACE mutation has also been positively associated 
with BMI despite resulting in lower serum ACE levels than the D/D genotype 
(146).  In contrast to the Olivetti Prospective Heart Study, the Heritage Family 
study did find that mothers with the T allele of the M235T AGT mutation had 
significantly greater fat mass than mothers homozygous for the M allele (211).  
Interestingly, AGT secretion from isolated adipocytes was not affected by the 
individual’s BMI, obesity, body fat, blood pressure, or AGT polymorphism, though 
adipocyte size was increased in individuals homozygous for the T allele (204). 
Several studies have failed to find any associations between RAS gene 
polymorphisms and obesity or BMI, possibly due to the population under study 
and the population size (84, 167, 267).   
 Metabolic studies on mice lacking one of the major components of the 
RAS (AGT, renin, ACE, AT1aR, AT2R) have demonstrated reductions in body 
weight and adiposity (Table 1.2), as well as improved insulin sensitivity.  These 
results suggest that AngII may play a role in the development of adipose tissue 
and consequently the development of obesity and obesity-related insulin 
resistance.  AGT-/- mice exhibit reductions in body weight at weaning and 
throughout 46 weeks of age when maintained on either standard murine diet or 
when fed a high fat diet (65% fat)  (160).  Differences in body weight were due to 
lower body fat and hypotrophy of adipocytes, which were attributed to increased 
locomoter activity in AGT-/- mice.  Of note, however, these mice were of the ICR-
CD1 strain (not the C57BL/6 typically used) and wild-type control mice were non-
littermates, which may be of significance because wild-type ICR-CD1 mice were 
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resistant to diet-induced obesity.  C57BL/6 mice lacking the Ren1c gene for renin 
also demonstrate lower body weights, both on standard murine diet and when 
fed a Western diet (42% fat) (253).  Food intake, activity, and expression of 
adipogenic genes in epididymal adipose tissue were not regulated by renin 
deficiency under HF conditions; however, Ren1c-/- mice had increased heat 
generation and decreased fat absorption, which may have contributed to the 
body weight phenotypes.  Additionally, AngII infusion (1.5 ug/day) in Ren1c-/- 
mice restored body weight and fat mass to levels of WT mice, implying that the 
effects of renin deficiency were due to reduced production and actions of AngII 
and not due to AngII-independent metabolic effects of renin.  ACE-/- mice fed 
standard murine diet displayed reduced body weight and fat mass with improved 
glucose tolerance; however, this study did not investigate the effects of ACE 
deficiency when mice were fed a high fat diet (125).  Wildtype and ACE-/- mice 
had similar locomoter activity but ACE-/- mice exhibited increased total and 
resting energy expenditures, which was attributed to increased fatty acid 
metabolism in liver.  These various models of reducing AngII synthesis indicate 
that AngII acts as a positive regulator of weight gain and adiposity; however, 
mechanisms for these effects are unclear and vary between models. 
 Mouse models of angiotensin receptor deficiencies have also been 
investigated for metabolic effects with less consistent results on body weight and 
adiposity.  Initial studies by Kouyama, et al. showed AT1aR-/-  mice have similar 
body weights compared to littermate controls when fed standard murine diet; 
however, they are partially protected from high fat (60% kcal as fat) diet-induced 
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obesity and glucose intolerance (144).  Food intake was not influenced by AT1aR 
deficiency, but body temperature and O2 consumption were increased.  
Adipocytes from high fat-fed AT1aR-/- mice were modestly hypotrophic.    Another 
group, Yamamoto, et al., also studied AT1aR-/- mice fed standard murine diet  
(4.8 % fat) diet and observed increases in body weight beginning at 3 weeks of 
age and persisting through 24 weeks of age due to hyperphagia in AT1aR-/- mice 
compared to controls (281).  Consistent with results of Kouyama et al., in a pair-
feeding study in which AT1aR-/- mice were limited to the same food intake of WT 
controls, AT1aR-/- mice exhibited reductions in body weight and fat mass (281).  
Both ad libitum fed and pair-fed AT1aR-/- had decreased levels of the 
anorexigenic peptide corticotrophin-releasing hormone (Crh) and luciferase 
assays confirmed regulation of hypothalamic Crh expression by AngII.  High fat 
fed mice in this study, however, did not exhibit hyperphagia or differences in 
body weight.  The reasons for the differences between these results and those of 
Kouyama, et al. are not entirely clear; however, Yamamoto, et al. describe 
different housing conditions as a possible confounder between studies.  
Surprisingly, mice lacking AT2R have also been demonstrated to exhibit reduced 
body weight and fat mass following high fat feeding (289).  Improvements in 
insulin resistance (calculated as a product of the area under plasma glucose and 
insulin curves as plotted from a glucose tolerance test) were observed in AT2R-/- 
mice fed either a low fat or high fat diet.  The results of Kouyama, et al. and 
Yvan-Charvet et al. are noteworthy because data suggests that AT1aR and 
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AT2Rs may have similar or overlapping functions in adipocytes, which is contrary 
to other cell types where AT1aR and AT2R signaling are in direct opposition (67).  
 Similar studies to those described above have been performed in AT1aR-/- 
or AT2R-/- mice on a hypercholesterolemic background, namely mice lacking 
apolipprotein E (ApoE-/-) or low density lipoprotein receptor (LDLR-/-).  
Hypercholesterolemia has been demonstrated to stimulate the RAS, increasing 
circulating AGT and angiotensin peptides (65) which may result in more 
pronounced effects of receptor deficiencies in a hypercholesterolemic setting.  
AT1aR/ApoE double knockout mice had significantly reduced fat mass and 
adipocyte size compared to ApoE-/- controls when fed standard murine diet (262).  
Reductions in adipocyte size in double knockout mice were associated with 
increased adipogenesis as evidenced by increased PPARγ, C/EBPα, and aP2 
mRNA abundance, suggesting that AngII inhibits adipocyte differentiation 
through the AT1aR in ApoE-/- mice (262).  In another study by the same group, 
there was no effect of AT2R deficiency in ApoE-/- mice fed standard murine diet 
(121).  However, with 4 weeks of high cholesterol diet (1.25% cholesterol) 
AT2R/ApoE-/- mice displayed increased fat mass, reduced adipocyte numbers, 
and reduced PPARγ mRNA abundance, suggesting that AngII promotes 
adipogenesis through the AT2R in ApoE-/- mice fed a high cholesterol diet (121).  
It is unclear why hypercholesterolemia causes these receptors to oppose one 
another when they appear to have similar effects in C57BL/6 mice fed low or high 
fat diets. 
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1.3.2.3 Regulation of body weight by pharmacologic blockade of the RAS 
 Another model for investigating the role of angiotensin receptors in the 
development and function of adipose tissue involves administration of 
pharmacological antagonists to various animal models rather than genetic 
ablation of the receptors.  Use of antagonists is more relevant to the treatment of 
human disease and an additional benefit is that the receptors are generally 
antagonized in adult mice, eliminating developmental artifacts that may 
contribute to adult phenotypes in murine knockout models.  ACE inhibitors are 
one class of drug that have been extensively studied in animal models.  Sprague-
Dawley rats fed standard rat diet and administered perindopril in the drinking 
water either from birth through 10 weeks of age exhibited reduced fat mass (162, 
278).  Wistar rats fed either standard or a high fat diet (35% kcal as fat) 
containing enalapril also exhibited reduced fat mass, though food intake was also 
reduced in enalapril-treated rats (223).  Mice fed a high fat diet (roughly 50% kcal 
as fat) for 12 weeks prior to captopril administration experienced dramatic weight 
loss when administered captopril that was maintained through 12 additional 
weeks of high fat feeding (206).  In mice administered captopril, reductions in fat 
mass were attributed to increases in lipolysis and fatty acid oxidation both in liver 
and adipose tissues; however, food intake was also reduced in captopril-treated 
animals. 
ARBs have also been extensively studied in regard to their ability to 
modulate adiposity, and given the previous discussion of the non-specific 
PPARγ-agonism of certain ARBs, it is not surprising that several studies using 
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telmisartan, irbesartan, and candesartan in animal models have demonstrated 
reductions in body weight, fat mass, and adipocyte size concurrent with 
upregulation of PPARγ and/or its target genes (12, 247, 296).  The PPARγ-
stimulating properties of valsartan seem to be less clear because while one study 
found no evidence of PPARγ-agonism (78), other studies using valsartan 
demonstrate reductions in fat mass and adipocyte size in Sprage-Dawley rats fed 
a high fat, high carbohydrate diet for 3 months (247) as well as upregulation of 
PPARγ mRNA abundance in adipose tissue of diabetic KK-Ay mice (262).  A 
study using temocapril (ACE inhibitor) and olmesartan (not a PPARγ ligand) in 
rats fed a fructose-rich diet, which is a non-obese model of insulin resistance, 
observed no changes in body or fat mass with either drug, but did see reductions 
in adipocyte size (88).  Sprague-Dawley rats administered losartan (not a PPARγ 
ligand) at 3 months of age for 2 weeks had attenuated weight gain, smaller 
adipose pads, and reduced cell size(59).  Losartan administered to aged rats fed 
standard diet between the ages of 24 and 30 months failed to affect body weight 
or fat mass, which supports the lack of PPARγ-agonism by losartan, (43).  The 
results with non-PPARγ-agonist ARBs suggest there may be an effect of AT1R 
blockade on adipose tissue growth; however, reductions in fat mass observed 
with valsartan, olmesartan, or losartan are modest and do not always translate to 
differences in body weight.  
1.3.2.4 Regulation of body weight by AngII infusion (elevated RAS) 
 Deficiency of major RAS components consistently results in reduced body 
weight and adiposity, possibly due to reduced action of AngII at certain cell types.  
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However, models whereby AngII is increased by chronic infusion also 
demonstrate paradoxical reductions in body weight and adiposity.  Initial studies 
in rats demonstrated that infusion of AngII (500ng/kg/min) to Sprague-Dawley 
rats for 14 days reduced body weight due to reductions in food intake while co-
administration with losartan, but not hydralazine, could attenuate these effects 
(34).  Cassis, et al. confirmed the blood pressure-independent and dose-
dependent reductions of body weight caused by AngII infusion in rats (47).  
Further studies by this group demonstrated reductions in food intake in AngII-
infused rats (77).  Interestingly, intracerebroventricular (icv) infusion of AngII 
caused reductions in body weight similar to peripheral AngII infusion, and while 
food intake was reduced when AngII was infused icv, pair-fed rats also lost 
weight indicating that reduced food intake alone is not the sole mechanism for 
AngII regulation of body weight (68).  This study and others (77) observed 
increased sympathetic nerve activity in brown and white adipocytes, which could 
increase energy expenditure and lipolysis, respectively, to contribute to AngII-
induced weight loss.  Lipolysis was quantified in vivo in AngII-infused Sprague-
Dawley rats using a microdialysis technique to measure interstitial glycerol levels 
and results indicated that AngII stimulated lipolysis in white adipose tissue in an 
AT1aR-dependent manner (37).  AngII-induced lipolysis in this study was also 
blocked by a nonselective β-adrenergic antagonist, suggesting interplay between 
presynaptic β-adrenoreceptors and AT1aRs. 
 The possible role of AngII to stimulate lipolysis has been examined in 
humans with conflicting studies demonstrating no effect (264), a weak stimulatory 
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effect (28-29) or an inhibitory effect of AngII on lipolysis (30-31, 95-96).  In one 
study of healthy male subjects, both sub-pressor and pressor doses of AngII 
infusion failed to alter whole-body lipolysis rates, plasma free fatty acids, plasma 
insulin, or plasma norepinephrine concentrations (264).  In contrast, subsequent 
studies utilized a microdialysis technique to study tissue-specific, rather than 
whole-body effects of AngII or ARB administration on blood flow (ethanol dilution 
technique) and lipolysis (glycerol accumulation).  Initial studies by Boschmann, et 
al. demonstrated slight reductions of blood flow in response to AngII and a failure 
of AngII to change glycerol concentrations, though accumulation of glycerol was 
expected as a result of reduced blood flow.  Thus, the authors concluded that a 
lack of change in glycerol levels in response to AngII suggests that AngII 
inhibited lipolysis (30-31).  However, follow-up studies by this same group 
contradicted these results and revealed weak stimulation of adipose lipolysis by 
AngII (0.1 – 1.0 µM) (28-29).   Studies of the lipolytic effects of AngII by another 
group also found that doses of AngII that reduced blood flow inhibited lipolysis, 
while higher doses of AngII paradoxically stimulated lipolysis (95-96).  A 
randomized, double-blind crossover study in which obese men were treated with 
either placebo or irbesartan for 10 days with a 2-4 week wash-out period 
between treatment phases found that blockade of endogenous AngII with 
irbesartan modestly reduced isoproterenol-induced glycerol production in 
adipose tissue, indicating an enhancement of lipolysis by AngII (28).  While to 
this point most groups speculated that AngII acted on presynaptic AT1Rs on 
sympathetic nerve terminals innervating adipose tissue to modulate 
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norepinephrine production and thus influence β-adrenergic stimulation of 
lipolysis, Goossens, et al. performed a study in isolated adipocytes and found 
that AngII administration reduced glycerol production in an AT1R-dependent 
manner, implying a direct role for AngII at adipocyte AT1Rs (95).  Unfortunately, 
differences in results from these studies examining AngII regulation of lipolysis 
have not been resolved, potentially influenced by direct versus indirect effects of 
AngII on lipolysis.   
1.4 The role of AngII in obesity-induced hypertension 
1.4.1 The association between obesity and hypertension 
(73)[171]The Framingham Heart Study indicated that 78% of hypertension 
cases in males and 64% in females can be directly attributed to obesity, yet the 
mechanistic links between the obesity and hypertension remain unclear (90).  
There is also a linear relationship between BMI and hypertension risk, such that 
the odds ratio for the presence of hypertension is 1.7 for overweight individuals, 
2.6 for those with a BMI of 30-34.9, 3.7 with a BMI of 35-39.9, and 4.8 with a BMI 
over 40 (179).  While effective antihypertensive medications are available, the 
prevalence of resistant hypertension, referring to hypertension that persists when 
treated with more than 3 antihypertensive agents, is expected to increase as the 
population becomes heavier and older (38), highlighting the need for either more 
effective medications than those currently available or better identification of 
specific characteristics of patient populations governing their responsiveness to 
medications.(38)[174]  
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1.4.2 Mechanisms of obesity-induced hypertension 
Postulated mechanisms linking obesity to hypertension include 
renal/hemodynamic changes, elevated levels of adipokines, insulin resistance, 
increased reactive oxygen species, enhanced sympathetic nervous activity, or 
activation of the RAS (71, 148, 178).  Impaired kidney function brought on by the 
development of glomerulosclerosis or compression of the kidney by abdominal 
visceral fat could result in impaired pressure natriuresis and increased blood 
volumes seen in obese patients.  While increased intra-abdominal pressure 
induced by artificial means (balloon) in dogs did result in increased blood 
pressure, the mechanisms and translatability of this study to human obesity are 
unclear (25).  Insulin resistance is part of the metabolic syndrome and is 
frequently present in obese-hypertensive patients; however, a direct role for 
insulin or hyperinsulinemia to promote high blood pressure has not been 
demonstrated (9, 105).  Factors produced by adipocytes, termed adipokines, 
represent an area of investigation that may identify mechanisms linking obesity to 
hypertension.  Adipokines linked to the development of hypertension include 
resistin, adiponectin, leptin, and angiotensinogen (193, 208, 257, 286).  Resistin 
is an adipose-derived vasoconsitrictor involved in insulin resistance, though its 
role in non-diabetic hypertension is unclear (254).  Adiponectin is a protective 
hormone associated with insulin sensitivity that can act as a vasodilator by 
upregulating eNOS production and reducing vascular reactive oxygen species 
(193), and obesity-associated hypoadipnectinemia may promote increases in 
blood pressure through ROS-induced endothelial dysfunction (148).  Leptin is an 
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anorectic protein hormone secreted by adipocytes, which acts on the 
hypothalamus to suppress food intake and can also stimulate sympathetic nerve 
activity to organs implicated in control of the cardiovascular system.  The role of 
leptin in obesity-hypertension is complex because while hyperleptinemia and 
resistance to the anorectic properties of leptin are characteristic features of 
obesity, the sympathetic stimulation by leptin appears to be maintained (209).   
1.4.3 The RAS as a link between obesity and hypertension 
While all of the above-mentioned mechanisms may contribute to obesity-
induced hypertension, the RAS is another important candidate that has been 
suggested to contribute to obesity-induced hypertension since adipocytes 
express all components needed to synthesize and respond to AngII (48). The 
systemic RAS has been demonstrated to be activated in rodent and human 
obesity (32, 271), and inhibitors of the RAS are effective treatments to reduce 
blood pressure in obese rodents and humans (33, 142).  In one study of 4 black 
populations, plasma AGT levels were highly correlated to BMI and interestingly, 
variation in BMI accounted for 90% of variation in AGT levels between 
populations (57).  Another group extended these findings by demonstrating a 
significant correlation between plasma AGT levels and obesity (268).  Adipose 
tissue distribution may play an important role in the relationship between BMI and 
plasma AGT levels since AGT mRNA abundance from visceral adipose tissue, 
but not subcutaneous, positively correlated with BMI (92).  However, conflicting 
results have been obtained (283). 
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Data from animal models demonstrate that adipose-derived RAS 
components contribute to circulating levels of AngII and provide further evidence 
that the RAS is activated with obesity.  Initial studies by Massiera, et al. 
demonstrated that AGT expression limited to adipocytes (AGT was 
overexpressed in adipocytes of AGT null mice) restores non-detectable plasma 
AGT levels of AGT null mice to 20-30% of that of wild-type mice (161).  This was 
confirmed by our group using a model of adipocyte AGT deficiency in mice in 
which plasma AGT levels were reduced roughly 25% (21).  In both studies by 
Massiera, et al. and Yiannikouris, et al., changes in AGT corresponded to 
changes in blood pressure, implicating adipose-derived AGT influences blood 
pressure.  Our laboratory has demonstrated elevated concentrations of 
angiotensin peptides in plasma from rats (32) and C57Bl/6 mice made obese 
from consumption of a high fat diet (100).  Moreover, obesity in both rodent 
models was associated with elevated blood pressure that was normalized by 
losartan, implicating the actions of AngII at the AT1R as a major contributor to 
obesity-induced hypertension (33).   
1.5 The role of AngII and adipose in vascular diseases 
1.5.1 The development, risk factors, and treatments of vascular disease in 
humans 
 Heart disease and cerebrovascular disease were among the top four 
leading causes of death in 2010 in the United States, leading to over  720,000 
deaths combined (176).  Atherosclerosis, an underlying cause of these 
conditions, is an inflammatory disease in which an initial endothelial insult results 
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in accumulation of cholesterol-rich macrophage foam cells in the sub-endothelial 
space of the aortic wall and develops into a plaque prone to thrombus (207).  
Atherosclerosis and arterial thrombosis can lead to restricted blood flow to the 
heart (coronary artery disease; CAD), peripheral artery disease (PAD), or 
cerebral ischemia (stroke) (115).  Risk factors for atherosclerosis include 
components of the metabolic syndrome previously discussed (Section 1.2) as 
well as physical inactivity, smoking, poor diet, heavy drinking, stress, sleep 
apnea, age, and family history (115).  Endothelial dysfunction, oxidation of LDL, 
inflammation, apoptosis, and coagulation are pivotal processes in the 
development of atherosclerosis, highlighting the participation of many different 
cell types ranging from vascular wall cells to immune cells to platelets and the 
need for cell-specific models to study each component of this disease. 
Aortic aneurysms and aortic dissections were responsible for over 10,000 
deaths in 2010, and are estimated to be present in approximately 1.1 million 
people (176, 261).  AAAs are defined as a permanent dilation of the aorta in 
which the diameter is 50% greater than a normal, healthy infrarenal aorta, or at 
least three centimeters, and are characterized by thickening and inflammation of 
the adventitial layer of the aortic tissue (129).  Risk factors for AAA formation 
include smoking, male gender, visceral obesity, and age > 65 years old (238). 
Experimentally induced AAAs, including those induced by infusion of AngII, 
exhibit elastin degradation within the medial layer of the aortic wall and 
macrophage infiltration into this region (224).  The success of pharmacological 
RAS antagonists in reducing atherosclerosis (81, 135, 172, 217, 288) and 
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experimental AAAs (102, 169, 261) have initiated studies into the role of AngII as 
an inflammatory stimulus contributing to the development of these vascular 
pathologies.   
1.5.2 The role of AngII and angiotensin receptors in vascular diseases 
 Several animal models reproduce findings in humans that ACE inhibitors 
reduce the severity of atherosclerosis (4, 50, 53, 145).  Hypercholesterolemia 
significantly increases the production of angiotensin peptides in a process 
mediated by AT1aRs, though the exact mechanism is unknown (65).  Our 
laboratories demonstrated that chronic infusions of AngII promoted 
atherosclerosis in LDLR-/- and ApoE-/- mice (62-63).  During the course of these 
studies, AAAs were discovered in a significant number of mice and infusion of 
AngII has become a well-established model of AAA formation used by several 
investigators.  Further experiments showed that AngII infusion promotes the 
formation of AAAs independent of increases in blood pressure, as 
norepinephrine infusion elevated blood pressure to the level of an AngII-infused 
mouse, but had no effect on the aortic diameter (45).  
 Mechanism(s) through which AngII promotes these vascular diseases are 
under intensive investigation.  A consistent finding is that AngII-induced 
atherosclerosis and AAAs in mice are markedly reduced in mice with whole body 
AT1aR deficiency (49, 65, 276), indicating that both pathologies are AT1aR-
mediated.  In contrast, there is controversy regarding the role of AT2R in these 
AngII-mediated vascular diseases (64-65, 120, 128).  In LDLR-/- mice fed a high 
fat, cholesterol containing diet for 12 weeks, deletion of AT2R had no effect on 
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atherosclerosis (65).  In contrast, another study found that AT2R deficiency in 
ApoE-/- mice fed a high fat/cholesterol diet for 10 weeks augmented the 
development of atherosclerosis (120).  These results suggest the AT2R is 
protective against atherosclerosis and thus enhanced activation of this receptor 
in AT1aR deficient mice contributes to reduced lesion formation, and accordingly, 
the effects of AT1aR antagonism are mitigated in AT2R deficient mice (120).  
Conflicting results were found using AT2R pharmacologic blockade with the 
compound PD123319 in chow-fed ApoE-/- mice infused with AngII, where the 
compound either had no effect (128) or exacerbated atherosclerosis (64).  The 
various study conditions and experimental designs used by these groups 
compromise the ability to interpret these results.  
While data are in agreement with a pivotal role of AT1R in AngII-induced 
atherosclerosis and AAAs, the cell type(s) mediating these effects remain 
unknown.  Bone marrow transplantation studies using AT1aR-/- mice as donors 
and wild-type LDLR-/- mice as recipients (effectively creating leukocyte-specific 
AT1aR-/- mice) showed only a modest reduction in atherosclerosis and no effect 
on AAA formation, suggesting that leukocyte AT1aR are not the primary target of 
AngII to promote these pathologies (49).  Similarly, deficiency of AT1aR on 
endothelial cells or smooth muscle cells also fails to affect the development of 
atherosclerosis or AAAs (unpublished observations), however endothelial 
AT1aRs do appear to mediate the development of ascending aortic aneurysms 
(212).  Adipose tissue surrounds the length of the aorta in a way that no fascial 
layer separates adipocytes from the vascular wall.  Adipocytes are gaining 
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interest as a source of inflammatory mediators and present another cell type 
through which AngII may induce atherosclerosis and AAAs.    
1.5.3 Role of adipose in the development of atherosclerosis 
 Over the past several years, the idea of crosstalk between perivascular 
adipose tissue and blood vessels has given rise to what is known as the “outside 
to inside” signaling mechanism of atherosclerotic plaque formation.  Investigators 
hypothesize that adipocytokines and chemokines released by adipose tissue can 
enhance various aspects of plaque development, such as endothelial 
dysfunction, vascular smooth muscle cell proliferation, and infiltration of 
inflammatory cells (273).  Adipose tissue surrounds most blood vessels, including 
the coronaries and the aorta, and the distance between the two is less than 0.1 
mm with no anatomical barrier to inhibit the diffusion of adipocytokines (109, 
210).  Early studies from our laboratory demonstrated that the presence of 
perivascular influenced the contractility of rat aorta to several vasoactive agents, 
including AngII (240).  Since this initial report, several lines of evidence 
demonstrate that perivascular adipose-derived vasoactive factors influence the 
tone of blood vessels, demonstrating a functional link between these two tissues 
(151, 274). 
 The association between perivascular adipose tissue and atherosclerosis 
has gained increasing attention.  In a segment analysis, pericoronary fat was 
associated with coronary atherosclerosis independent of overall epicardial 
adipose volume (158) and there is a higher incidence of plaques on the 
epicardial side of coronaries versus the myocardial side (205), suggesting a 
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causative role for epicardial adipose in plaque formation.  Additional studies have 
revealed that pericardial fat volume, measured by cardiac computed tomography 
(CT), is associated with high-risk coronary lesions, independent of both BMI and 
the extent of plaque burden, supporting the conclusion that adipose has a local 
effect on the vessel (227).  In fact, regions with low pericardial adipose had no 
high-risk coronary lesions (227).   
More importantly, several studies have demonstrated that epicardial and 
perivascular adipose secrete more inflammatory mediators than other adipose 
depots (17, 51, 109, 165) and these proinflammatory mediators are increased 
with high fat feeding and obesity (51, 244).  Specifically, secretion of the 
chemokine MCP-1, a macrophage chemoattractant with a pivotal role in the 
development of AngII-induced and human vascular diseases (117, 157), is 
upregulated 10-40 fold in perivascular adipose compared to perirenal and 
subcutaneous fat (51).  Our lab has also demonstrated that MCP-1 secretion 
from abdominal peri-aortic fat is elevated in mice fed a high fat diet (203).  
Interestingly, another technique has recently been developed to study the role of 
adipose tissue in the development of atherosclerosis which involves 
transplantation of adipose depots between mice.  Initial studies by Ohman, et al. 
demonstrated that the transplantation of visceral, but not subcutaneous, adipose 
tissue into the subcutaneous region of ApoE-/- increases atherosclerotic lesion 
formation through elevation of systemic adipocytokines, in the absence of 
confounding factors such as high fat feeding, obesity, or diabetes (189).  
Subsequent studies by this group revealed that transplantation of visceral 
38 
 
epididymal adipose directly adjacent to the right common carotid artery 
dramatically increased atherosclerosis, though again subcutaneous adipose had 
no effect (188).  These studies by Ohman, et al. provide further evidence that 
adipose tissue surrounding vessels can contribute to lesion development, 
possibly through “outside to inside” signaling mechanisms, though it remains to 
be determined if the AngII/AT1R axis activates these pathways. 
1.5.4 Role of adipose in AAA formation 
The Health in Men Study of more than 12,000 men found that both waist 
circumference and waist-to-hip ratio are positively associated with AAA size, after 
adjustment for other risk factors such as age, dyslipidemia, smoking, 
hypertension, coronary heart disease, and diabetes mellitus (93).  Moreover, 
more severe aneurysms (those ≥ 40mm compared to 30 mm) had an even 
greater association, suggesting that obesity may play a role in the severity as 
well as the development of AAA (93).  Data from our laboratory corroborates 
findings that obesity promotes aneurysm formation (203) and furthermore that 
weight loss attenuates the adventitial expansion of formed AAAs in a model of 
AngII-induced AAAs in high-fat fed mice (202).  Police, et al. demonstrated in 
both genetic (ob/ob) and high fat diet-induced obesity models that obesity 
increases AngII-induced AAA formation (203).  Somewhat surprisingly, male 
C57BL/6 mice fed high fat diet for 4 months displayed similar aneurysm 
incidence to hypercholesterolemic LDLR-/- mice.  These results were attributed to 
the inflammatory nature of abdominal peri-aortic fat compared to thoracic 
abdominal fat, as AAAs develop specifically in the abdominal region where the 
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surrounding adipose secretes significantly more MCP-1.  Additionally, 
macrophage accumulation was greater in the abdominal region of AngII-infused 
mice compared to saline-infused mice and the number of recruited macrophages 
to white adipose tissue was greater in mice that did develop AAAs compared to 
those that did not.  These data suggest that in obese mice, AngII initiates 
macrophage infiltration into peri-aortic adipose surrounding regions associated 
with AAA formation.  It is unclear, however, whether or not these effects are due 
to direct action of AngII at the adipocyte AT1aR.   
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Table 1.1 Summary of studies investigating the effects of AngII on adipocyte differentiation in vitro. 
Publication Adipocyte 
source 
Effect of AngII 
treatment 
Measurements Receptors Antagonist 
used 
Additional information 
Darimont 
1994 
Ob1771 
(mouse) 
Pro-adipogenic GPDH activity AT2R PD123177 AngII elicits prostacyclin from 
mature adipocytes to promote 
differentiation of 
preadipocytes 
Jones 1997 3T3-L1 
(mouse) 
Pro-adipogenic TG, FAS and 
GPDH activity 
AT2R* P-186 *Losartan had similar effects 
to P-186 
Crandall 
1999 
Human 
preadip. 
Pro-adipogenic Cyclin D 
expression 
AT1R Losartan AngII increases cell cycle 
progression; PD123319 had 
no effect 
Schling 2001 Human 
preadip. 
Anti-adipogenic GPDH activity N/A None  
Saint-Marc 
2001 
Rat 
preadip. 
Pro-adipogenic Number of 
GPDH-lipid 
positive cells 
N/A N/A AngII effects blocked by 
aspirin and restored by 
additional prostacyclin 
treatment 
Janke 2002 Human 
preadip. 
Anti-adipogenic Lipid content AT1R Irbesartan PD123319 had no effect; 
neither antagonist was used in 
combination with AngII 
Matsushita 
2006 
Human 
MSCs 
Anti-adipogenic 
Pro-adipogenic 
PPARγ, FAS, 
Adiponectin 
AT2R 
AT1R 
PD123310 
Valsartan 
AngII+PD restored adipogenic 
markers to level of vehicle 
Brucher 
2007 
Human 
preadip. 
Anti-adipogenic GPDH activity AT1R Losartan Anti-adipogenic effect greater 
in preadipocytes from obese s 
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Table 1.1 (continued) 
Publication Adipocyte 
source 
Effect of AngII 
treatment 
Measurements Receptors Antagonist 
used 
Additional information 
Saiki 2008 3T3-L1 
(mouse) 
Anti-adipogenic PPARγ AT1aR Valsartan AngII also transiently increase 
LPL activity 
Sarzani 2008 Human 
preadip 
and adip 
Pro-adipogenic Cell number 
 
AT1R Valsartan Cell number of mature and 
differentiated preadipocytes 
were measured in response to 
AngII 
Fuentes 2010 Human 
preadip. 
Anti-adipogenic GPDH activity, 
PPARγ 
N/A N/A Mechanism involves ERK1/2 
activation 
Hung 2011 3T3-L1 
(mouse) 
N/A 
(Endogenous) 
Lipid content Both Losartan 
PD123319 
Losartan and PD reduced lipid 
content to the same extent 
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Table 1.1 Summary of genetic ablation models of RAS components reporting body weight regulation. 
Publication  Model Diet 
(weeks; beyond 
weaning) 
Effect on body 
weight 
Effect on fat 
mass 
Effect on adipocyte 
size 
Massiera 2001 AGT-/- Chow  
High fat  
Reduced 
Reduced 
Reduced 
Reduced 
N/A 
Takahashi 2007 Renin (Ren1c-/-) Chow (8-20) 
Western (8-32) 
Reduced 
Reduced 
 
Reduced 
 
Reduced 
Jayasooriya 2008 ACE-/- Chow Reduced Reduced N/A 
Kouyama 2005 AT1aR-/- Chow (8) 
High fat (8) 
No difference 
Reduced 
No difference 
Reduced 
No difference 
Reduced 
Yamamoto 2011 AT1aR-/- Chow (12) 
High fat (6) 
Increased 
No difference 
Increased 
N/A 
Increased 
N/A 
Daugherty 2004 AT1aR-/- x LDLR-/- Western (12) No difference N/A N/A 
Tomono 2008 AT1aR-/- x ApoE-/- Chow (20) Increased Reduced Reduced 
Yvan-Charvet 
2005 
AT2R-/- Low fat (12) 
High fat (12) 
No difference 
Reduced 
No difference 
Reduced 
Reduced 
Reduced 
Iwai 2009 AT2R-/- x ApoE-/- Chow (24) 
High Cholesterol (4) 
No difference 
No difference 
No difference 
Increased 
No difference 
Increased 
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Table 1.2 Criteria for diagnosis of the metabolic syndrome from IDF and AHA/NHLBI Joint Scientific Statement  
Defining parameter Requisite Levels 
Elevated waist circumference Non-Europeans: men ≥ 94 cm; women ≥ 80 cm 
European origin: men ≥ 102 cm; women ≥ 88 cm 
Elevated blood pressure*, mmHg ≥ 130/≥85 
Elevated fasting blood glucose*, mg/dL ≥ 110 
Elevated triglycerides*, mg/dL ≥ 150 
Reduced HDL cholesterol*, mg/dL 
Men 
Women 
 
<40 
<50 
IDF, International Diabetes Federation; AHA, American Heart Association; NHLBI, National Heart, Lung, and Blood Institute. 
*Drug treatment for indicated parameter is an alternate indicator. 
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Figure 1.1 The renin-angiotensin system.  AngII is formed from subsequent cleavage of angiotensinogen by renin and 
ACE.  AngII can act through two receptors, AT1R or AT2R, while smaller fragments such as AngIV or Ang(1-7) can act 
through IRAP or the mas receptor, respectively. 
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Figure 1.2 Structure of AngII and the AT1R.  A, The linear amino acid 
structure of AngII.  Boxed residues are involved in AT1R activation. B,  
Schematic of AT1R (adapted from de Gasparo, 2000). Labeled open 
circles are conserved residues, closed circles are involved in binding 
AngII, and the circled amino acids (298-302) are involved in G-protein 
activation. Receptor activation requires interactions between aromatic 
Tyr and Phe residues of AngII and the Asn111 and His256 residues within 
the transmembrane binding pocket of the AT1R. 
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Figure 1.3 AT1R signaling pathways. A, G-protein dependent pathways, adapted from Dinh, et al. 2001.  B, G-
protein independent pathways, from Hunyady, et al. 2006. 
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Figure 1.4 Regulation of adipocyte differentiation.  Factors involved in the commitment of MSCs to the adipocyte 
lineage and the terminal differentiation of preadipocytes to mature adipocytes are shown; from Cristancho and Lazar 
2011.
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STATEMENT OF THE PROBLEM 
The metabolic syndrome is a collection of risk factors that elevate an 
individual’s risk for cardiovascular disease (Table1.3).  Obesity is a central 
component of the metabolic syndrome as well as an independent risk factor for 
cardiovascular disease.  Understanding how obesity changes normal adipocyte 
physiology represents a major focus of current research aiming to ameliorate the 
burden of obesity-associated disease.  Adipocytes express all major components 
of the renin-angiotensin system and are capable of both producing and 
responding to AngII, though the functional purpose of this system in adipose 
tissue is unclear.   Adipose tissue is both a lipid storage and endocrine organ and 
AngII could potentially modulate several of its functions, such as regulation of 
adipogenesis, lipogenesis, lipolysis, insulin sensitivity, adipokine secretion, and 
production of other RAS components.   
Investigations into the effects of AngII on adipocyte differentiation have 
yielded controversial results, leaving unanswered questions regarding whether 
AngII affects adipocyte differentiation and through which receptor subtype (Table 
1.1).  Further studies into the metabolic effects of AngII in vivo using murine 
models of whole-body angiotensinogen, renin, or ACE deficiency reveal that mice 
with reduced capacity to synthesize AngII exhibit protection from diet-induced 
obesity, improved glucose tolerance, and improved blood pressure when fed a 
high fat diet.   Similar results were obtained from studies of AT1aR- or AT2R-
deficient mice; however conflicting data have been reported.  Paradoxically, 
chronic infusion of AngII into mice results in reduced body weight and adiposity, 
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similar to mice lacking major RAS components.  In these studies, the 
mechanisms and tissues responsible for the observed effects remain unknown. 
AngII also promotes vascular disease through the AT1aR, as mice 
deficient in this receptor are protected from hypercholesterolemia-induced 
atherosclerosis and AngII-induced abdominal aortic aneurysms (AAAs).  Similar 
to the metabolic effects of AngII, however, it is unclear which tissues or cell types 
participate in these effects.  Obesity is a well-established risk factor for 
cardiovascular disease and there is accumulating evidence for direct 
contributions of adipose tissue, specifically adipose surrounding blood vessels, in 
the development of these diseases.  Our lab has demonstrated that obesity not 
only promotes AngII-induced AAA formation, but abdominal peri-aortic adipose 
tissue from the region susceptible to aneurysm formation secretes higher levels 
of chemokines compared to non-aneurysmal thoracic regions, implying there 
may be a direct effect of AngII on adipocytes to enhance AAA development. 
The impact of adipocyte AT1aR activation on adipose tissue functions 
could have significant health consequences, especially in the context of obesity 
and its contribution to cardiovascular risk.  The models used to study this 
receptor, however, fall short of identifying cell-specific mechanisms for the 
observed effects of AngII.  To gain a better understanding of the physiologic and 
pathologic effects of AngII on adipocytes and their contributions to obesity and 
vascular disease, we created a model of adipocyte-AT1aR deficiency using the 
Cre/LoxP system.  The overall hypothesis of this dissertation is that adipocyte 
AT1aRs mediate the development, function, and inflammatory profile of 
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adipocytes and thus contribute to the development of obesity-related disorders 
and vascular diseases.  The following specific aims were designed to test this 
hypothesis: 
Specific Aim 1: Determine the role of adipocyte AT1aRs on the development 
and function of adipose tissue. 
A.  Determine the effect of adipocyte-AT1aR deficiency on parameters of 
the metabolic syndrome in lean and obese mice. 
B.  Determine the effect of AngII and AT1aR deficiency on adipocyte 
differentiation using both 3T3-L1 and isolated stromal vascular cells from 
adipocyte-AT1aR deficient mice. 
Specific Aim 2: Determine the role of the adipocyte AT1aR on the development 
of vascular disease. 
A. Define temporal effects of high fat versus high fat/cholesterol diets on 
the systemic and adipose RAS in LDLR-/- mice. 
B. Determine the effect of adipocyte-AT1aR deficiency on the 
development of atherosclerosis in hypercholesterolemic LDLR-/- mice fed 
Western diet for 3 months. 
C. Determine the effect of adipocyte-AT1aR deficiency on atherosclerosis 
and AAAs induced by AngII infusion. 
 
 
 
Copyright © Kelly Anne Putnam 2012  
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SECTION II. SPECIFIC AIM 1 
Determine the role of the adipocyte AT1aR on the development and function of 
adipose tissue. 
2.1 Summary 
Adipocytes express angiotensin receptors, but the direct effects of 
angiotensin II (AngII) stimulating this cell type remain unclear.  Adipocytes 
express angiotensin type 1a (AT1aR) and angiotensin type 2 receptors (AT2R), 
both of which have been implicated in obesity.  In this study, we determined the 
effects of adipocyte AT1aR deficiency on adipocyte differentiation and the 
development of obesity in mice fed standard mouse diet, low (LF) or high fat (HF) 
diets.  Mice expressing Cre recombinase under the control of the aP2 promoter 
were bred with AT1aR floxed mice to generate mice with adipocyte AT1aR 
deficiency (AT1aRaP2).  AT1aR mRNA abundance was reduced significantly in 
both white and brown adipose tissue from AT1aRaP2 mice compared to non-
transgenic littermates (AT1aRfl/fl).  In mice fed standard mouse diet, there was no 
significant effect of adipocyte AT1aR deficiency on body weight, fat mass, or 
glucose tolerance in 12 month old mice.  To stress the system, mice of each 
genotype were infused with saline or AngII for one month, after which modest 
adipocyte hypertrophy was observed in saline-infused AT1aRaP2 mice and this 
effect was significantly more pronounced in AngII-infused mice.  To define the 
effect of adipocyte AT1aR on the development of obesity, mice of each genotype 
were fed LF or HF diets for 16 weeks.  The mRNA abundance of other AngII 
receptors, AT2R or angiotensin type 1b (AT1bR), were unaffected by deficiency 
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of adipocyte AT1aRs.  Additionally, angiotensinogen mRNA abundance in 
adipose tissue was not significantly affected by adipocyte AT1aR deficiency.  
Adipocyte AT1aR deficiency did not influence body weight, glucose tolerance, or 
blood pressure in mice fed either LF or HF diets.  However, LF-fed AT1aRaP2 
mice exhibited striking adipocyte hypertrophy even though total fat mass was not 
different between genotypes.    Stromal vascular cells from AT1aRaP2 mice 
differentiated to a lesser extent to adipocytes compared to controls.  Conversely, 
incubation of 3T3-L1 adipocytes with AngII increased Oil red O (ORO) staining 
and promoted mRNA abundance of PPARγ that was antagonized by losartan.  
These results suggest that reductions in adipocyte differentiation in LF-fed 
AT1aRaP2 mice resulted in increased lipid storage and hypertrophy of remaining 
adipocytes.  These results demonstrate that AngII regulates adipocyte 
differentiation and morphology through the adipocyte AT1aR in lean mice. 
  
 53 
 
2.2 Introduction  
The renin-angiotensin system (RAS) has well-established roles in fluid 
homeostasis, blood pressure regulation, and the development of various forms of 
cardiovascular diseases.  Several cell types express components of the RAS 
(16) allowing for angiotensin II (AngII) to elicit endocrine, autocrine, and/or 
paracrine effects.  Adipocytes express angiotensin receptors, with differences in 
angiotensin receptor subtype expression depending on the species and source of 
adipose tissue (44, 76, 297).  In rodents, angiotensin type 1a receptors (AT1aR) 
and angiotensin type 2 receptors (AT2R) have been localized to adipocytes (59, 
61), while angiotensin type 1b receptors (AT1bR) are not readily detectable in 
murine adipose tissue (36).  The functional and/or pathophysiological role of 
angiotensin receptor subtypes in adipocytes is unclear.   
One possible role of angiotensin receptors on adipocytes may be to 
regulate the production of angiotensinogen (AGT) from adipocytes, which are an 
important extrahepatic source of circulating AGT (21, 160-161).  Increased AGT 
mRNA abundance in adipose tissue of AT2R deficient mice was reduced by an 
AT1R-antagonist, suggesting that AngII upregulates AGT expression through the 
AT1aR (154).  Furthermore, AngII infusion dramatically increased AGT mRNA 
levels specifically in adipose tissue and not liver (154).  It remains to be 
determined whether these results are due to direct effects of AngII at adipocyte 
AT1aRs or through indirect effects at other cell types.  
 Regulation of body weight through changes in fat mass represents 
another role of AngII, possibly through adipocyte receptors.  Genetic ablation of 
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RAS components including angiotensinogen, renin, angiotensin converting 
enzyme (ACE), and AT1aR in mice results in reduced body weight due to 
reductions in fat mass when mice are fed standard or high fat (HF) diets (125, 
144, 161, 253), although there are contrary data (65, 154). Even more 
perplexing, infusion of high doses of AngII can also result in weight loss and 
reduced adiposity (34, 37, 47, 68), making it difficult to define the role of AngII in 
the regulation of adipocyte growth and/or differentiation.  These apparent 
contradictions have yet to be resolved and are complicated by direct versus 
indirect effects of AngII on adipose growth and development. 
In studies aimed at examining direct effects of AngII to regulate adipocyte 
differentiation using clonal cell lines or ex vivo differentiation of preadipocytes, 
conflicting results have also been obtained.  Several studies indicate that AngII 
enhances adipocyte differentiation and lipid accumulation (61, 130, 221), while 
others suggest that AngII inhibits adipocyte differentiation (85, 122, 220, 229).  
There are also conflicting reports regarding which of the AngII receptors are 
responsible for these effects, as investigators have reported that AngII stimulates 
adipogenesis through the AT1R or AT2R (61), while other studies have reported 
that AngII inhibits adipocyte differentiation (122).  The use of AT1R antagonists 
with AT1R-independent effects on adipocyte differentiation (i.e., activation of 
peroxisome proliferator activated-receptor γ, PPARγ (123, 231)) complicates 
interpretation of results from these studies.  
Based on results from mouse models demonstrating that whole body 
deficiency of components of the RAS reduces body weight and fat mass, we 
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hypothesized that AngII promotes differentiation through direct effects at 
adipocyte AT1aR, which may have therapeutic implications in the development 
and/or treatment of obesity.  To test this hypothesis, we generated mice with 
adipocyte deficiency of AT1aR.  In HF-fed mice, deficiency of AT1aR in 
adipocytes had no effect on the development of obesity, glucose intolerance, and 
obesity-induced hypertension.  Notably, LF-fed mice lacking AT1aR in adipocytes 
exhibited pronounced adipocyte hypertrophy, and stromal vascular cells (SVC) 
isolated from mice with adipocyte AT1aR deficiency exhibited reduced capacity 
to differentiate to adipocytes.  These results suggest that AngII promotes 
adipocyte differentiation through direct effects at adipocyte AT1aR in lean mice.  
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2.3 Materials and Methods 
2.3.1 Mice and diets 
 All experiments were conducted according to National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and were approved by the 
University of Kentucky Institutional Animal Care and Use Committee.  AT1aR 
floxed (AT1aRfl/fl) mice (212) were crossed initially to FLPe mice (B6.SJL-
Tg(ACTFLPe)9205Dym/J, The Jackson Laboratory, Bar Harbor, ME) to remove 
the neocassette and subsequently female AT1aRfl/fl mice were bred to 
hemizygous transgenic male mice of Cre mice under control of an 
aP2/promoter/enhancer.Cg-Tg (Fabp4-cre 1Rev/J; The Jackson Laboratory, Bar 
Harbor, ME; Figure 2.1A).  For all studies, male and female AT1aRfl/fl littermates 
were used for comparison to mice with adipocyte AT1aR deficiency.  Male mice 
of each genotype were fed standard murine diet (18% kcal from fat; Harlan 
Laboratories, Inc., Indianapolis, IN; Table 2.1) ad libitum through 12 months of 
age and subsequently infused with either saline or AngII for 1 month.  In separate 
studies, male mice (8-10 weeks of age) of each genotype were fed either LF 
(10% kcal as fat; D12450B; Research Diets, New Brunswick, NJ) or HF diets 
(60% kcal as fat; D12492; Research Diets) ad libitum for 16 weeks with free 
access to water.  AT1aRaP2 mice were bred to ROSA26 mice (B6.129S4-
Gt(ROSA)26Sor<tm1Sor>/J, The Jackson Laboratory, Bar Harbor, ME) and  β-
galactosidase activity was measured to confirm lineage expression of Cre 
recombinase  in adipose tissue.  Briefly, adipose tissues collected from aP2-Cre 
null (Cre 0/0) and aP2-Cre positive (Cre+/0) AT1aRfl/+ mice heterozygous for the 
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ROSA26 allele were sectioned and stained overnight with X-gal.  Blue staining 
indicated successful removal of a stop codon from the β-galactosidase gene by 
Cre recombinase.   
2.3.2 In vivo measurements 
2.3.2.1 Standard murine diet with AngII infusion study 
 For mice fed standard mouse diet, body weights were recorded every 
other week beginning at 6 months of age.  Body composition was measured at 6, 
9, 12, and 13 months of age.  Glucose tolerance test was performed as 
described above at 12 months of age.  At 13 months of age, osmotic mini-pumps 
(Model 2004, DURECT Corporation, Cupertino, CA) filled with either saline or 
AngII (delivered at 1,000 ng/kg/min; Sigma, St. Louis, MO) were implanted 
subcutaneously under isoflurane anesthesia.  Mice were sacrificed at the end of 
the 28-day infusion after a 4-hour fast.  Blood pressure was measured by tail-cuff 
(Visitech Systems, Inc., Apex, NC) prior to and 3 weeks after pump implantation. 
2.3.2.2 LF and HF diets study 
Body weights were recorded weekly for all mice.  The body composition of 
a subset of mice was analyzed by NMR spectroscopy (EchoMRI®) before mice 
began the LF or HF diets and after 14 weeks on diet.  Glucose tolerance tests 
were performed after 8 and 15 weeks on diet.  Mice were fasted 6 hours and 
blood glucose measurements were measured at 0 min (before injection of 
glucose solution) and at 15, 30, 60, and 120 minutes after i.p. injection of glucose 
(1 g/kg body weight).  After 14 weeks on diet, insulin tolerance tests were 
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performed after a 4-hour fast.  Insulin was administered at a dose of 0.5 U/kg 
body weight via i.p. injection and blood glucose was measured at 0 min (before 
injection of insulin) and at 30, 60, and 120 minutes after insulin injection.  Blood 
pressure was measured by telemetry for 3-days.  After 15 weeks on diet, 
telemetry implants (model TA11PA-C10, Data Sciences International, St. Paul, 
MN) were surgically inserted as described previously (100).  After 16 weeks on 
diet, baseline blood pressures were recorded for 3 consecutive day and night 
periods.  Mice were excluded if their mean pulse pressure was below 17 mmHg, 
as an indication of a poor signal from the telemeter to the receiver. 
2.3.3 Plasma measurements 
  Mice were terminated after a 4 hour fast.  Plasma renin concentrations 
were measured by incubating plasma (8 µl) with exogenous angiotensinogen (25 
nM) in the presence of ACE inhibitors and then angiotensin I (AngI) was 
quantified by radioimmunoassay (DiaSorin, Via Crescentino, Italy).  Plasma 
insulin concentrations were quantified with the Ultra Sensitive Mouse Insulin 
ELISA kit (Crystal Chem, Downers Grove, IL) and plasma leptin concentrations 
were quantified with a Mouse Leptin ELISA kit (Millipore).  Non-esterified fatty 
acids (NEFAs) were quantified with the NEFA-HR(2) kit (Wako Diagnostics, 
Richmond, VA).  Plasma AGT concentrations were determined with the Mouse 
Total Angiotensinogen Assay Kit (Immuno-Biological Laboratories Co., Ltd., 
Japan).   
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2.3.4 Quantification of mRNA abundance 
 To quantify mRNA abundance, RNA was isolated using the SV Total RNA 
Isolation System (Promega, Madison, WI).  Reverse transcription was performed 
on RNA (0.4 µg) using qScript cDNA SuperMix as per manufacturer’s instructions 
(Quanta Biosciences, Gaithersburg, MD).  Real-time PCR was performed with 
PerfeCTa SYBR Green FastMix for iQ on 2ng of cDNA template (Quanta 
Biosciences, Gaithersburg, MD).  A standard curve was generated from a series 
of ten-fold dilutions of cDNA with each real-time PCR plate and this was used to 
extrapolate the relative starting quantity of mRNA for the gene of interest from 
the given Ct values.  Data are expressed as the ratio of the gene of interest 
starting quantity to that of 18S. 
2.3.5 Differentiation of preadipocytes from stromal vascular cells (SVC).   
Subcutaneous adipose tissue was dissected from the inguinal region, 
minced, and incubated in Basal Medium (OM-BM, Zenbio, Research Triangle 
Park, NC) supplemented with collagenase (1 mg/mL) and 
penicillin/streptomyocin mixture (5%) for at least 1 hour with shaking at 37 ⁰C as 
described previously (215).  Two days after cells had achieved 100% confluency, 
media were changed to Differentiation Medium (OM-DM, Zenbio, Research 
Triangle Park, NC) and replaced every other day for 8 days.  Cells were either 
harvested for RNA using TRIzol or fixed for Oil Red O (ORO) staining.  For ORO 
measurements, cells were fixed in formalin (10%) and stained in filtered ORO 
(0.3%) solution for 30 minutes at room temperature.  For quantification, 
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isopropanol (1 ml) was added to the plates to extract ORO stain, this solution 
was transferred to a microtiter plate, and absorbance was measured at 510 nm. 
2.3.6 3T3-L1 adipocytes 
3T3-L1 adipocytes were obtained from American Type Culture Collection 
(Manassas, VA) and maintained in DMEM containing FBS (10%) and 
penicillin/streptomyocin mixture (5%).  Two days after cells were100% confluent,  
differentiation of preadipocytes was initiated by administration of a cocktail 
containing insulin (0.1 µM, Sigma-Aldrich, St. Louis, MO), dexamethasone (1 µM; 
Sigma-Aldrich, St. Louis, MO), and isobutyl methyl xanthine (0.5 mM; Sigma-
Aldrich, St. Louis, MO).  Incubation with AngII (1 µM, Sigma-Aldrich, St. Louis, 
MO) or losartan (1 µM) was performed with fresh media containing drugs 
replaced every other day.  After 6 days of differentiation cells were harvested for 
RNA isolation using TRIzol reagent (Invitrogen, Carlsbad, CA) or for 
quantification of ORO staining as described above. 
2.3.7 Statistical analyses   
Data were analyzed by ANOVA for comparisons between the 4 
diet/genotype groups, as appropriate, using the Holm Sidak test for post-hoc 
analysis.  When time was an additional variable, data were analyzed by repeated 
measures ANOVA.  Data are represented as mean ± SEM.  If normality or equal 
variance tests failed, simple transforms were performed or the non-parametric 
Kruskal-Wallis test was used with Dunn’s post-hoc analysis.  Statistical 
significance was defined as P<0.05. 
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2.4 Results 
2.4.1 Generation and characterization of mice with adipocyte AT1aR 
deficiency   
To confirm effective and specific deletion of exon 3 of AT1aR in 
adipocytes, AT1aR mRNA abundance was quantified in adipose tissues, liver, 
brain, heart, and kidney from mice fed standard laboratory diet (2 months of age).  
AT1aR mRNA abundances were not significantly different in liver, kidney, or 
brains from AT1aRfl/fl compared to AT1aRaP2 mice (Figure 2.1B).  In heart, 
AT1aR mRNA abundance was reduced modestly, but significantly, in AT1aRaP2 
compared to AT1aRfl/fl mice.  In interscapular brown (BAT) and epididymal white 
(WAT) adipose tissue, AT1aR mRNA abundance was decreased significantly in 
AT1aRaP2 compared to AT1aRfl/fl mice.  Moreover, positive β-galactosidase 
staining was present in subcutaneous white and interscapular brown adipose 
tissues of Cre +/0 mice (Figure 2.1C).   
Deficiency of AT1aR in adipocytes had no significant effect on body 
weight (Figure 2.2A), body composition (Figure 2.2B), or glucose tolerance 
(Figure 2.2C), quantified prior to infusions of saline or AngII in AT1aRfl/fl and 
AT1aRaP2 mice.  To stress the system, mice of each genotype were infused with 
saline or AngII for 1 month.  Systolic blood pressure increased significantly in 
AngII-infused mice of each genotype, and was not significantly different between 
genotypes (Table 2.2).  As anticipated in response to infusion of AngII, plasma 
renin concentrations decreased significantly in AngII-infused mice compared to 
saline-infused mice, with no differences between genotypes (Table 2.2).  Infusion 
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of AngII had no significant effect on plasma NEFA concentrations, which were 
not significantly different between genotypes (Table 2.2).  The mean adipocyte 
size in AT1aRaP2 mice infused with saline (3890 ± 157 µm2) was increased 
modestly, but not significantly, compared to AT1aRfl/fl mice (3365 ± 117 µm2; P = 
0.052, Figure 2.3G).  Infusions of AngII resulted in a modest reduction in body 
weight and fat mass in mice of each genotype (Figure 2.3A,B), with no significant 
differences between genotypes.  Interestingly, AngII infusion resulted in a striking 
reduction in adipocyte size in AT1aRfl/fl mice (2167 ± 209 µm2; P <0.001) 
compared to saline (Figure 2.3D versus 2.3C), but this effect was not apparent in 
AT1aRaP2 mice (3514 ± 183 µm2; Figure 2.3D).  However, the increased 
adipocyte size in AngII-infused AT1aRaP2 mice compared to AngII-infused 
AT1aRfl/fl controls (P < 0.001) was not associated with any differences in body 
weight, fat mass, or plasma NEFA levels (Table 2.2).  
2.4.2 Adipocyte-AT1aR deficiency had no effect on the development of obesity 
or obesity-associated parameters 
 To define effects of adipocyte AT1aR deficiency on development of 
obesity, mice of each genotype were fed a LF or HF diet for 16 weeks.  HF-fed 
mice of each genotype had significantly increased body weight and fat mass 
compared to LF-fed controls (Figure 2.4A, B).  However, adipocyte AT1aR 
deficiency had no significant effect on body weight (Figure 2.4A) or fat/lean mass 
(Figure 2.4B) in either LF or HF-fed mice.  While the mass of retroperitoneal 
(RPF) and epididymal (EF) adipose tissues were significantly increased by HF 
feeding, there was no significant effect of genotype in either diet group (Table 
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2.3).  Glucose tolerance was significantly impaired in HF-fed mice of each 
genotype compared to LF-fed controls (Figure 2.4C,D).  However, adipocyte 
AT1aR deficiency had no significant effect on glucose tolerance in either LF or 
HF-fed mice.  Similarly, while HF feeding significantly impaired insulin tolerance 
tests in both genotypes, there was no significant difference in insulin tolerance 
between LF or HF AT1aRaP2 mice compared to AT1aRfl/fl controls on respective 
diets (Figure 2.4E).  Plasma insulin and leptin concentrations were increased 
significantly by HF-feeding in mice of each genotype, but there were no 
significant differences between genotypes in either diet group (Table 2.3).  
Plasma concentrations of non-esterified fatty acids (NEFAs) were not 
significantly influenced by diet or genotype (Table 2.3).    
 Systolic blood pressures (SBPs) during the day and night cycle were 
significantly increased in HF-fed mice of each genotype compared to LF-fed 
controls (Figure 2.4F; P < 0.05).  However, deficiency of AT1aR in adipocytes 
had no significant effect on SBP in either LF or HF-fed AT1aRaP2 mice compared 
to AT1aRfl/fl controls.   
2.4.3 Adipocyte-AT1aR deficiency resulted in striking adipocyte hypertrophy in 
lean mice. 
Since adipocytes also express AT2Rs, which have been proposed to 
contribute to obesity development in mice (289), we quantified mRNA abundance 
of AT2R and AT1bR in adipose tissue from mice of each genotype.  In AT1aRfl/fl 
controls, AT2R mRNA abundance was increased significantly in visceral adipose 
tissue from HF-fed mice compared to LF-fed controls (Figure 2.5A).  However, 
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there was no significant effect of AT1aR deficiency in adipocytes on AT2R mRNA 
abundance in either visceral or subcutaneous adipose tissues of LF or HF-fed 
mice.  Similarly, AT1b mRNA abundance was not significantly influenced by diet 
or genotype in visceral or subcutaneous adipose tissue (Figure 2.5B).   
Quantification of AGT mRNA abundance in adipose depots revealed that 
AGT expression was suppressed by HF-feeding in both visceral and 
subcutaneous adipose depots (Figure 2.6A; P < 0.05), and adipocyte-AT1aR 
deficiency had no effect on AGT expression in liver or adipose. Similarly, there 
were no differences between genotypes in plasma AGT concentrations, although 
HF diet increased plasma AGT (Figure 2.6B; P < 0.05).   
 We quantified adipose morphology in LF or HF-fed mice of each 
genotype.  In visceral retroperitoneal adipose tissue from LF-fed mice, adipocyte 
AT1aR deficiency resulted in a greater number of large adipocytes (Figure 2.7A-
E).  Mean adipocyte size in LF-fed AT1aRaP2 mice (2925 ± 361 µm2) was 
increased significantly compared to adipocyte size in AT1aRfl/fl controls (1328 ± 
146 µm2, P < 0.05; Figure 2.7E).  Increases in adipocyte size in LF-fed AT1aRaP2 
mice resulted in a significant reduction in the number of adipocytes within a 
measurement frame compared to cell numbers in sections from LF-fed AT1aRfl/fl 
controls (Figure 2.7F).  With HF feeding, the number of large adipocytes 
increased in both genotypes, but there were no significant differences between 
genotypes (Figure 2.7A-E).  Mean adipocyte size increased in HF-fed mice of 
each genotype compared to LF-fed controls (HF, AT1aRfl/fl, 2923 ± 447 µm2; 
AT1aRaP2, 3407 ± 432 µm2; P < 0.05, Figure 2.7E), but the number of adipocytes 
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within a measurement frame was not different between genotypes (Figure 2.7F).  
Notably, the size of adipocytes from LF-fed AT1aRaP2 mice was similar to 
adipocyte sizes in HF-fed AT1aRfl/fl controls.  However, despite the increase in 
adipocyte size, adipose tissue mass was not significantly increased in LF-fed 
AT1aRaP2 mice compared to AT1aRfl/fl controls (Table 2.3).    
 2.4.4 Deficiency of AT1aR in adipocytes decreased differentiation of SVCs 
to adipocytes, while AngII promoted differentiation of 3T3-L1 adipocytes 
 Increases in size of adipocytes from LF-fed mice with adipocyte AT1aR 
deficiency could result from reductions in lipolysis, alterations in lipid synthesis 
and/or uptake, or from decreased capacity of preadipocytes to differentiate to 
adipocytes.  Plasma NEFA were not different between LF-fed mice of each 
genotype, suggesting that lipolysis was not influenced by adipocyte AT1aR 
deficiency.  We examined the ability of preadipocytes within SVCs isolated from 
mice of each genotype to differentiate into mature adipocytes.  AT1aR mRNA 
abundance was significantly decreased in adipocytes (day 8) differentiated from 
SVCs of AT1aRaP2 mice compared to AT1aRfl/fl controls (AT1aRfl/fl, 0.30 ± 0.02; 
AT1aRaP2, 0.16 ± 0.01 AT1aR/18S RNA ratio; P < 0.001).  Deficiency of AT1aR 
resulted in significantly reduced ORO staining on day 8 of differentiation 
compared to SVCs differentiated from AT1aRfl/fl controls (Figure 2.8A; P <  
0.0001).  In addition, mRNA abundance of PPARγ was significantly decreased in 
adipocytes differentiated from AT1aRaP2 mice compared to AT1aRfl/fl controls 
(Figure 2.8B; P < 0.05).  Reductions in ORO staining occurred in the absence of 
changes in mRNA abundance of either fatty acid synthase or CD36 (Figure 
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2.8C,D, respectively).  Conversely, incubation of 3T3-L1 preadipocytes with AngII 
throughout the differentiation protocol significantly increased ORO staining and 
mRNA abundance of PPARγ in mature adipocytes (Figure 2.8E,F, respectively; 
P < 0.05).  AngII-mediated increases in PPARγ mRNA abundance were 
abolished when 3T3-L1 adipocytes were incubated with the AT1R antagonist, 
losartan (Figure 2.8F).  However, incubation of preadipocytes with losartan in the 
absence of AngII had no significant effect on PPARγ mRNA abundance in 
differentiated adipocytes.       
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2.5 Discussion 
 Results from this study demonstrate that adipocyte AT1aR deficiency 
promotes the development of adipocyte hypertrophy in mice fed either standard 
mouse diet and infused with AngII or in mice fed a LF diet.  Surprisingly, the 
phenotype of adipocyte AT1aR deficiency to increase adipocyte size was only 
apparent in lean mice (LF-fed or AngII-infused).  The size of adipocytes in LF-fed 
mice AT1aRaP2 mice was similar to the size of adipocytes in non-transgenic 
littermate mice fed a HF diet.  However, despite increases in adipocyte size in 
AT1aRaP2 mice, fat mass was similar in mice of each genotype fed standard 
mouse diet or the LF diet.  Thus, adipocyte hypertrophy in lean AT1aRaP2 mice, 
in the absence of increases in total adipose tissue mass, was insufficient to 
promote differences in body weight, glucose tolerance or blood pressure.  
Preadipocytes from adipocyte-AT1aR deficient mice demonstrated reduced 
capacity to differentiate to adipocytes, suggesting that the increased adipocyte 
size in lean AT1aRaP2 mice occurred as a consequence of increased lipid storage 
in a reduced number of adipocytes.  Conversely, incubation of 3T3-L1 adipocytes 
with AngII promoted ORO staining and PPARγ expression in differentiating 
adipocytes, supporting a role for AngII to promote adipocyte differentiation.  
Surprisingly, the effects of adipocyte AT1aR deficiency to increase adipocyte cell 
size in LF-fed mice were not observed when mice were fed a HF diet.  These 
results suggest that adipocyte AT1aR regulate adipocyte differentiation under 
lean, but not obese conditions.     
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Adipose tissue expresses several components of the RAS necessary to 
produce and respond to AngII.  Results from this study confirm previous reports 
that murine adipocytes express both AT1aR and AT2R, with low levels of AT1bR 
(36, 61).  Adipocyte AT1Rs have been suggested to regulate expression of RAS 
components in adipocytes, adipocyte differentiation or growth, or adipocyte 
glucose uptake or metabolism (61, 133, 154).  Murine models of global genetic 
AT1aR deletion and systemic administration of angiotensin receptor blockers 
(ARBs) to rodents have been previously used to study effects of this receptor on 
the development of obesity (144, 175, 296).  Specifically, whole body deficiency 
of angiotensinogen, renin, or ACE in mice fed standard mouse diet resulted in 
reduced body weight, fat mass, glucose intolerance, and decreased blood 
pressure (125, 161, 253).  In addition, whole body deficiency of angiotensinogen, 
ACE, AT1aR or AT2R reduced the development of obesity in mice fed a HF diet 
(144, 161, 206).  Conversely, previous results from our laboratories 
demonstrated that deficiency of AT1aR or AT2R in low density lipoprotein 
receptor deficient mice fed a HF diet had no effect on body weight (65).  These 
conflicting data are confounded by an inability to define the cell type(s) 
responsible for effects of whole body deficiency of individual RAS components.  
To address the direct role of AngII effects at adipocyte AT1aR, we created mice 
with deficiency of AT1aR in adipocytes, and demonstrate a lack of effect on body 
weight or fat mass when mice are fed a LF or HF diet.  These results 
demonstrate that previously observed effects of whole body AT1aR deficiency to 
decrease the development of obesity (144) result from reduced effects of AngII at 
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other cell types.  Additionally, it is possible that improvements in glucose 
tolerance and blood pressure observed in mice with whole body AT1aR 
deficiency (144) are secondary to the previously observed leaner phenotype of 
these animals, as adipocyte AT1aR deficiency had no effect on these obesity-
associated parameters. 
Since whole body AT2R deficiency has also been reported to reduce the 
development of obesity (289), albeit with conflicting results (65) a possible 
explanation for the lack of effect of adipocyte-AT1aR deficiency on the 
development of obesity may be compensation by this receptor in adipocytes.  In 
the present study, quantification of mRNA abundance of AT1bR and AT2R from 
whole adipose tissue lysates did not reveal transcriptional upregulation of either 
receptor to compensate for the loss of adipocyte AT1aRs.  Thus, it is unlikely that 
effects of adipocyte AT1aR deficiency were masked by compensation through 
AngII effects at other receptor subtypes.   
Adipose AGT production has been shown to be regulated by AngII 
through the AT1aR (154); however, the results of this study demonstrate that 
these effects are independent of direct actions at adipocyte AT1aRs.  Consistent 
with other reports, HF diet reduced AGT mRNA abundance in both visceral and 
subcutaneous adipose tissues (191) while plasma AGT levels were actually 
increased (287).  This apparent discrepancy is likely due to increased overall 
AGT production due to the dramatic increase in fat mass resulting from HF diet 
despite downregulation of gene transcription (283).  Increased production of AGT 
by other tissues is also possible in the setting of obesity. 
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 A surprising finding from this study was that AT1aRaP2 mice have large 
adipocytes when fed a LF diet or when fed standard diet and infused with AngII.  
Quantification of mean adipocyte size indicated that the magnitude of adipocyte 
hypertrophy in LF-fed AT1aRaP2 mice was similar to the hypertrophy observed in 
HF-fed control mice.  Also, AT1aRaP2 mice exhibited adipocyte hypertrophy 
compared to AT1aRfl/fl controls when infused with AngII.  It is unclear why 
infusion of AngII was required to bring forth significant differences in adipocyte 
size in chow-fed mice, though this is likely related to the modest weight loss 
experienced by AngII-infused mice, suggesting the phenotypes of adipocyte-
AT1aR deficient mice are most prominent when mice are leaner.  
Despite these striking increases in adipocyte size, there were no 
differences in fat mass between genotypes on either chow or LF diets.  The 
finding of similar fat masses in lean mice of each genotype, despite marked 
adipocyte hypertrophy in AT1aRaP2 mice, suggests that a smaller number of 
adipocytes in LF AT1aRaP2 mice accumulated more lipid to maintain adipose 
mass at a similar level between genotypes (13).  In accordance with the lack of 
an effect on fat mass, there was no evidence of glucose intolerance, and no 
changes in plasma insulin or leptin concentrations in LF-fed AT1aRaP2 mice, 
signifying that in lean mice adipocyte hypertrophy alone is insufficient to alter 
levels of these proteins associated with an obese phenotype.    
 Adipocyte hypertrophy in lean mice with adipocyte AT1aR deficiency could 
result from several mechanisms, including reduced lipolysis, reduced numbers of 
adipocytes (with remaining adipocytes filling up with lipid), or increased lipid 
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synthesis or uptake in resident adipocytes.  Since plasma concentrations of 
NEFA were not different in LF-fed mice of either genotype, lipolysis was most 
likely not influenced by AT1aR deficiency in adipocytes.  The literature on AngII 
regulation of lipolysis is conflicting, with some reports demonstrating minimal 
effects of AngII on adipose tissue lipolysis in humans (264), as compared to 
reductions in lipolysis of human adipose tissue in response to AngII in normal 
weight (31) and obese subjects (95).  In this study, mRNA abundance of fatty 
acid synthase and CD36 were not altered in AT1aR deficient adipocytes, 
suggesting that reduced synthesis and/or uptake of lipids most likely did not 
contribute to differences in Oil Red O staining.  Others have reported that AngII 
induces fatty acid synthase expression in 3T3-L1 adipocytes, however it was 
unclear whether these effects were through AT1aR or AT2R (130) and little has 
been reported regarding regulation of CD36 by AngII in adipocytes.    
Since results did not support changes in lipid uptake, mobilization and/or 
synthesis in adipose tissue from LF-fed mice with adipocyte AT1aR deficiency, 
we focused on adipocyte differentiation as a potential mechanism contributing to 
hypertrophy of remaining adipocytes.  Indeed, preadipocytes isolated from mice 
lacking adipocyte AT1aR differentiated ex vivo had reduced lipid accumulation 
and PPARγ mRNA abundance, indicating a reduced capacity for differentiation.  
Results from this study conflict with those of Kouyama, et al. who examined 
mouse embryonic fibroblasts (MEFs) isolated from wild type and whole body 
AT1aR deficient mice and found no difference in their ability to differentiate into 
adipocytes (144).  Differences between results from these studies may reflect the 
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differences between culture systems (i.e., preadipocytes from the SVF compared 
to MEFs).  In addition, results from this study demonstrate that previously 
observed protection against the development of obesity in whole body AT1aR 
deficient mice occurred independent of adipocyte AT1aR.  
Notably, we observed no differences in adipocyte morphology in HF-fed 
AT1aRaP2 mice which may be due to the suppression of adipocyte differentiation 
that other groups have found occurs in the setting of obesity or prolonged HF 
feeding (101, 116, 127, 197), however conflicting reports highlight the complex 
dynamics of adipocyte cell numbers and turnover in obesity (15, 222, 243).  
Interestingly, some suggest that adipocyte hypertrophy in HF-fed humans and 
rodents is a result of reduced adipogenesis and that the remaining cells 
accumulate more lipid over time (13).  Our results support this conclusion that 
reduced adipocyte differentiation results in adipocyte differentiation in lean mice.  
In HF-fed mice, however, the inhibition of adipocyte differentiation occurs as a 
result of an inability to suppress canonical anti-adipogenic WNT signaling (101).  
WNT signaling is an important determinant of mesenchymal stem cell 
commitment to the adipocyte lineage and appears to precede the regulatory 
effects of AngII on adipocyte differentiation since no changes in adipocyte size in 
HF-fed AT1aRaP2 mice were observed.   
Our results demonstrate that AngII promotes differentiation of murine 3T3-
L1 adipocytes in an AT1R-dependent manner.  Several in vitro experiments 
using adipocyte cell lines have implicated a role for AngII in lipid accumulation 
and differentiation of adipocytes, with conflicting results.  Initial studies from 
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Darimont, et al. demonstrated that AngII promoted adipocyte differentiation of 
Ob1771 mouse adipocytes by eliciting PGI2 from mature adipocytes via AT2Rs 
(61).  In another study, AngII increased glycerol-3-phosphate dehydrogenase 
(GPDH)-positive, lipid-containing cells in mouse adipose tissue explants, though 
the role of specific AngII receptors were not investigated (221).  A pro-adipogenic 
effect of AngII was confirmed in 3T3-L1 and human adipocyte primary cells 
where AngII increased triglyceride content, fatty acid synthase activity, GPDH 
activity, and lipid accumulation, though in these studies both AT1R and AT2R 
antagonists abolished AngII-induced effects (114, 130).  Other reports, however, 
indicate that AngII decreased lipid content as well as PPARγ and fatty acid 
synthase in 3T3-L1 and isolated human adipocytes (85, 122, 220).  While 
discrepancies in the literature may be due to the variety of culture systems, 
sources of adipocytes, differentiation cocktails, and experiment durations used by 
each group, this field of research is also complicated by the AT1R-independent 
stimulation of PPARγ by some AT1R antagonists (22, 216, 231).  For example, 
Wistar Kyoto rats administered candesartan exhibited increased expression of 
PPARγ expression in adipose tissue and consequently had a larger number of 
small adipocytes (296).  Similar results have been reported with telmisartan and 
irbesartan (123, 175, 242).  It would be interesting in future studies to examine 
effects of AT1R antagonists with PPARγ-stimulating properties in AT1aR 
deficient adipocytes to better define the AT1R-independent effect of this class of 
compounds.   
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In conclusion, adipocyte AT1aR deficiency had no effect on development 
of obesity or obesity-induced hypertension and dysregulated glucose 
homeostasis.  However, in lean mice, deficiency of AT1aR in adipocytes 
promoted striking adipocyte hypertrophy, without the negative consequences 
typically associated with this phenotype.  Mechanisms for effects of adipocyte 
AT1aR deficiency include reductions in differentiation of preadipocytes to mature 
adipocytes, resulting in increased lipid accumulation across a smaller number of 
adipocytes in LF-fed mice.  Conversely, AngII promoted the differentiation of 
3T3-L1 adipocytes through an AT1R-dependent mechanism.  These results 
demonstrate that AngII acts at adipocyte AT1aR to regulate adipose tissue 
growth in lean mice, which may have implications in diseases associated with 
cachexia. 
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Table 2.1 Composition of diets. 
 Standard chow Low Fat High Fat 
Source Harlan Teklad 
Global 18% Protein 
Rodent Diet, 2018 
Research Diets, 
Inc. D12450B 
Research Diets, 
Inc. D12492 
Kcal/g 3.1 3.85 5.24 
Protein (% of total 
kcal) 
24 20 20 
Carbohydrate (% of 
total kcal) 
58 70 20 
Fat (% of total kcal) 18 10 60 
Fat sources Soybean oil Soybean oil (55% 
of fat kcal), lard 
(45% of fat kcal) 
Lard (91% of fat 
kcal), soybean oil 
(9% of fat kcal) 
 
  
 76 
 
 
Table 2.2 Effects of adipocyte AT1aR deficiency on fat mass and plasma 
measurements in mice fed standard murine diet. 
 Saline  AngII  
 AT1aRfl/fl AT1aRaP2 AT1aRfl/fl AT1aRaP2 
EF mass (g) 1.68 ± 0.4 1.72 ± 0.4 1.25 ± 0.2 1.344 ± 0.1 
RPF mass (g) 0.40 ± 0.08 0.48 ± 0.08 0.40 ± 0.07 0.48 ±0.04 
Final systolic blood 
pressure (mmHg) 105 ± 2 104 ± 0.9 126 ± 5* 123 ± 5* 
Plasma renin  
(AngI ng/mL) 2.00 ± 0.93 2.44 ± 0.70 0.084 ± 0.05* 0.30 ± 0.35* 
Plasma NEFAs 
(mEq/L) 0.036 ± 0.003 0.04 ± 0.005 0.041 ± 0.003 0.037 ± 0.002 
Values are means ± SEM (n = 4-5 per group). Effect of AngII, *P < 0.05. 
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Table 2.3 Effects of adipocyte AT1aR deficiency on fat mass and plasma 
measurements in LF- and HF-fed mice. 
 LF   HF  
 AT1aRfl/fl  AT1aRaP2   AT1aRfl/fl  AT1aRaP2  
EF mass (g)  1.01 ± 0.18  1.07 ± 0.21   1.66 ± 0.07*  1.54 ± 0.06*  
RPF mass (g)  0.40 ± 0.09  0.39 ± 0.08   1.46 ± 0.06*  1.46 ± 0.13*  
Plasma leptin 
(ng/mL)  
11.8 ± 2.2  13.3 ± 2.8   56.0 ± 1.5*  49.5 ± 3.5*  
Plasma insulin 
(ng/mL)  
0.34 ± 0.04  0.55 ± 0.26   1.06 ± 0.19*  1.96 ± 0.42*  
Plasma NEFAs 
(mEq/L)  
1.38 ± 0.14  1.47 ±0.12   1.51 ± .21  1.40 ± 0.27  
Animals were fasted for 4 hours prior to sacrifice.  Values are means ± SEM (n 
= 10-15 per group). Effect of diet, *P < 0.05.  
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Figure 2.1 Development of mice with adipocyte deficiency of 
AT1aR.  A, Mice with loxP sites flanking exon 3 of the AT1aR gene (a) 
were bred to mice expressing flippase (FLP) which recognizes the FRT 
sites to remove the neocassette (b).  (c) AT1aRfl/fl mice were bred to 
transgenic mice expressing Cre recombinase driven by the aP2 promoter 
to generate adipocyte AT1aR deficient mice (AT1aRaP2) and non-
transgenic littermates (AT1aRfl/fl).  B, AT1aR adipocyte deficiency was 
confirmed in brown (BAT) and white adipose tissues (WAT, respectively). 
C, Cre recombinase activity was confirmed with X-Gal staining in BAT 
and subcutaneous adipose of AT1aRaP2 bred to ROSA26 mice (Cre+/0) 
but not in mice lacking Cre recombinase (Cre 0/0).  Data are represented 
as mean ± SEM from n = 8-10 mice/group.  *, P < 0.05 compared to 
AT1aRfl/fl. 
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Figure 2.2 Adipocyte-AT1aR deficiency has no effect on body parameters 
of aged mice fed standard murine diet.  A, Body weights were recorded every 
other week beginning at 6 months of age. B, Fat and lean mass were increased 
and decreased, respectively, at 12 months of age compared to 6 months of age, 
*, P < 0.05. C, Glucose tolerance test performed at 12 months of age. Data are 
represented as mean ± SEM from 4-5 mice/group. 
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Figure 2.3 AngII infusion reduces adipocyte size in AT1aRfl/fl but not 
AT1aRaP2 mice fed standard diet.  A, AngII infusion for 4 weeks in mice fed 
standard murine diet causes modest, but not significant, weight loss. B, Neither 
AngII infusion nor adipocyte AT1aR deficiency affects % fat or lean mass in 
aged mice. C, Frequency distribution of saline- and (D) AngII-infused mice.  E, 
Images of saline- and (F) AngII-infused H&E stained adipocytes (scale bar 
represent 200µm).  G, Saline-infused AT1aRaP2 mice exhibit modest adipocyte 
hypertrophy (P = 0.052) and AngII infusion reduces adipocyte size in AT1aRfl/fl 
mice (*, P < 0.001 effect of treatment; **, P < 0.001 effect of genotype).  Data 
are represented as mean ± SEM from 3-5 mice/ group. 
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Figure 2.4 Deficiency of AT1aR in adipocytes had no effect on development 
of obesity or obesity-associated glucose intolerance.  A, Body weight over 
15 weeks of LF or HF feeding in mice of each genotype.  Beginning at week 3, 
HF-fed mice of each genotype had significantly increased body weight compared 
to LF-fed controls. B, Fat and lean mass (% body weight) of AT1aRfl/fl and 
AT1aRaP2 mice fed LF or HF diets for 16 weeks. C, Blood glucose concentrations 
at selected time points following a bolus of glucose (time 0) in AT1aRfl/fl and 
AT1aRaP2 mice fed a LF or HF diet for 15 weeks.  D, Area under the curve (AUC, 
arbitrary units) quantification of blood glucose concentrations shown in C.  Data 
are represented as mean ± SEM from n = 9-12 mice/group.  *P < 0.05 or **P < 
0.001 compared to LF within genotype. 
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Figure 2.5 Deficiency of AT1aR in adipocytes has no effect on mRNA 
abundance of other angiotensin receptors in adipose tissues.  mRNA 
abundance of AT2R (A) and AT1bR (B) was quantified in visceral and 
subcutaneous adipose tissues from LF and HF-fed AT1aRfl/fl and AT1aRaP2 mice.  
Data are represented as mean ± SEM from n = 5-7 mice/group. *, P < 0.05 
compared to LF within genotype and tissue. 
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Figure 2.6 HF diet suppresses adipose AGT mRNA abundance and 
increases plasma AGT concentration. A, AGT mRNA abundance was 
quantified in liver, visceral and subcutaneous adipose tissues (#, P < 0.05 
compared to either adipose depot; *, P < 0.05 compared to LF within adipose 
depot; †, P < 0.05 compared to visceral adipose or liver). B, Plasma AGT 
concentrations (*, P < 0.05 effect of diet).  Data are represented as mean ± SEM 
from n = 4-10 mice/group. 
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Figure 2.7 Adipocyte AT1aR deficiency resulted in striking adipocyte 
hypertrophy in LF-fed mice.  Histograms of adipocyte number of selected 
areas quantified in adipose tissue sections using image analysis software 
(sections from n = 3 mice/group and 3 image fields per section) from LF (A) or 
HF-fed mice (B). Representative images of H&E stained sections of 
retroperitoneal visceral adipose tissue used for quantification of adipocyte sizes 
from LF (C) or HF-fed mice (D) of each genotype.  Scale bar in lower right 
represents 200 µm.  E, Quantification of mean adipocyte area.  F, Quantification 
of adipocyte number per measurement frame.  Data are represented as mean ± 
SEM from n = 9 mice/group.  *P < 0.005 compared to LF within genotype.  **P < 
0.05 compared to AT1aRfl/fl  within diet group.  
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Figure 2.8 Deficiency of AT1aR reduced differentiation of SVC to 
adipocytes while AngII promotes differentiation of 3T3-L1 adipocytes.  A, 
ORO staining (510 nm) of adipocytes differentiated from SVCs of AT1aRfl/fl and 
AT1aRaP2 mice.  Data are represented as mean ± SEM from n = 3-5 
samples/genotype.  PPARγ (B), fatty acid synthase (C), and CD36 (D) mRNA 
abundance in adipocytes (day 8) differentiated from SVCs of AT1aRfl/fl and 
AT1aRaP2 mice.  Data are mean ± SEM from n = 8-11 samples/group.  (E) ORO 
staining of 3T3-L1 adipocytes differentiated in the absence (vehicle) or presence 
of AngII (1 µM).  F, PPARγ mRNA abundance in 3T3-L1 adipocytes differentiated 
in the absence or presence of AngII, losartan, or AngII + losartan (1 µM of each 
compound).  Data are represented as mean ± SEM from n = 4-5 samples/group.  
A-C:  *, P < 0.05 compared to AT1aRfl/fl.  F,G:  *, P < 0.05 compared to vehicle; 
**, P < 0.05 compared to AngII. 
 
 
 
 
 
 
 
Copyright © Kelly Anne Putnam 2012  
 91 
 
SECTION III. SPECIFIC AIM 2 
Determine the role of the adipocyte AT1aR on the development of 
vascular diseases. 
3.1 Summary 
 While obesity is a well-established risk factor for cardiovascular diseases, 
few studies have investigated the possible involvement of adipose tissue 
surrounding blood vessels in the progression of this disease.  The amount of 
epicardial or perivascular fat is positively correlated to the amount of 
atherosclerotic lesion area in the underlying vessels and perivascular fat has 
been shown to have a pro-inflammatory phenotype, though it remains unclear if 
perivascular adipose inflammation plays a causative role in lesion formation.  
AngII is known to promote various forms of vascular diseases, independent of 
blood pressure increases, though the cell type through which AngII acts remains 
unknown.  We tested the hypothesis that AngII acts as a proinflammatory 
stimulus through the adipocyte AT1aR, and deficiency of this receptor in 
adipocytes is protective against the development of atherosclerosis and 
abdominal aortic aneurysms (AAAs).  To understand how hypercholesterolemia 
affects the expression and production of RAS components, particularly in 
adipose tissue, LDLR-/- mice were fed standard mouse diet (termed “chow”), 
Western, or high fat (HF) diets for 1 to 3 months.  Body weights of HF- and 
Western-fed mice were significantly greater than those of chow-fed mice, though 
only Western diet induced hypercholesterolemia and hypertriglyceridemia.  
AT1aR mRNA abundance varied across adipose depots, but was markedly 
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suppressed in both thoracic and abdominal peri-aortic fat (PAF) depots after 3 
months of Western or HF diets.  In Western diet-fed mice previously 
demonstrated to exhibit an activated systemic renin-angiotensin system (RAS), 
plasma renin concentrations (PRC) were increased, while HF-fed mice exhibited 
elevations in plasma angiotensinogen (AGT) concentrations.  AT1aRfl/fl x LDLR-/- 
mice and AT1aRaP2 x LDLR-/- mice were fed Western diet for 3 months to 
examine the role of endogenous AngII acting at the adipocyte AT1aR in the 
development of atherosclerosis, though no differences between genotypes were 
observed in this study.  A model of AngII infusion known to augment 
atherosclerosis and induce AAA formation in mice fed Western diet for 5 weeks 
was used to determine the role of the adipocyte AT1aR in exogenous AngII-
induced vascular pathologies; however, there were no differences in lesion 
formation or AAA development between genotypes.  Previous studies revealed 
that adipocyte-AT1aR deficiency resulted in adipocyte hypertrophy in lean but not 
obese mice, and interestingly, modest adipocyte hypertrophy was also noted in 
retroperitoneal adipose of AngII-infused AT1aRaP2 x LDLR-/- mice.  These effects 
were independent of adipose tissue lipolysis and similar to results in lean mice.  
Results from these studies demonstrate that adipocyte-AT1aR deficiency does 
not influence the development of atherosclerosis in LDLR-/- mice fed Western diet 
chronically or infused with AngII for 1 month during diet feeding.  Also, deficiency 
of adipocyte AT1aRs did not alter the formation or severity of AngII-induced 
AAAs.  Adipocyte hypertrophy was modest in AT1aRaP2 x LDLR-/- mice compared 
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to lean mice in other studies, suggesting that the effect of adipocyte-AT1aR 
deficiency to reduce adipocyte differentiation is partially reduced by Western diet.  
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3.2 Introduction 
 Heart disease and stroke are among the leading causes of death 
worldwide with other forms of vascular disease not far behind (176).  
Understanding the mechanisms behind the initiation and progression of these 
diseases is essential for the development of effective therapeutic strategies.  
Pharmacologic blockade of the RAS through ACE inhibitors and ARBs reduces 
the risk of cardiovascular mortality (5), implying a causative role for AngII in these 
diseases.  Murine models of hypercholesterolemia have been shown to stimulate 
the production of circulating angiotensin peptides and furthermore, infusion of 
AngII into hypercholesterolemic mice promotes the formation of atherosclerotic 
lesions (62) and induces aortic aneurysms (63).  The exact mechanisms through 
which AngII promotes these vascular diseases are still being elucidated.  
Deletion of the AT1aR gene in LDLR-/- and ApoE-/- mice markedly reduces 
atherosclerotic lesion area and attenuates the formation of abdominal aortic 
aneurysms (AAAs) (65, 276).  The AT2R, on the other hand, protects against 
these pathologies (64, 112, 120), though these results are controversial (65).  
Interestingly, although the AT1aR clearly has pathological effects, the cell type(s) 
mediating the increases in atherosclerosis and AAAs remain elusive (49, 87, 138, 
212).   
 Adipocytes are an understudied contributor to vascular disease, though 
interest in perivascular adipose tissue has increased in the past few years (194, 
251).  Quantification of epicardial and perivascular adipose depots through 
various imaging techniques has allowed several groups to establish significant 
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positive correlations between the presence/amount of adipose tissue in 
epicardial, pericardial, or perivascular depots and the presence/severity of 
atherosclerotic lesions in corresponding blood vessels (56, 150, 158, 227, 285).  
A functional paracrine relationship between perivascular adipose and the 
inclusive vessel was first recognized with the discovery that perivascular adipose 
modulates vessel contractility through the release of vasoactive signaling 
molecules (151, 153, 240, 274).  Furthermore, the proinflammatory phenotype of 
perivascular compared to visceral or subcutaneous adipose depots (51, 103, 
109) suggests the influence of perivascular adipose extends beyond modulation 
of vessel contraction to impact the infiltration of immune cells to the vessel wall, a 
critical component of both lesion and aneurysm formation.  Indeed, adipose 
transplant studies have provided direct evidence for the contribution of adipose 
tissue to the development of atherosclerosis (188-189).  A large clinical trial of 
over 12,000 men has demonstrated an independent association between obesity 
and AAA formation (93).  Correspondingly, obesity promoted the development of 
AngII-induced AAAs in normocholesterolemic mice fed a HF diet (203).  Results 
from this mouse model indicate perivascular adipose tissue surrounding the 
abdominal region of aortas from obese mice secretes more chemokines than the 
thoracic region and thus may contribute to the inflammation and formation of 
aneurysms in this region (203).  These studies suggest that AngII may act 
directly on perivascular adipocytes through the AT1aR to promote the formation 
of atherosclerotic lesions and AAAs.  The following studies investigated the 
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possible role of the adipocyte-AT1aR on the development of atherosclerosis and 
AAA in hypercholesterolemic LDLR-/- mice. 
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3.3 Materials and Methods 
3.3.1 Mice and diets 
 All mice were fed respective diets ad libitum and given free access to 
water.  Mice were group-housed and exposed to 12 hours of light and dark each 
day.  Experimental protocols were approved by the University of Kentucky 
Institutional Care and Use Committee. 
 LDLR-/- time course diet.  Eight week old LDLR-/- (Stock #; Jackson 
Laboratory, Bar Harbor, ME) were purchased and placed on either standard 
mouse diet (termed “chow”), Western diet (D ; Teklad) comprised of 42% kcal as 
fat and 0.15% cholesterol, or high fat (HF) diet (Research Diets) comprised of 
60% kcal as fat (Table 3.1).  Groups of mice were maintained on diet for either 1, 
2, or 3 months (n = 8).   
 Diet-induced atherosclerosis.  Mice with adipocyte-AT1aR deficiency 
(AT1aRaP2) were bred to LDLR-/- mice to generate AT1aRaP2 x LDLR-/- and 
AT1aRfl/fl x LDLR-/- mice.  At 8-10 weeks of age, all mice were fed Western diet 
for a total of 3 months. 
 AngII-induced AAA and atherosclerosis.  AT1aRaP2 x LDLR-/- and AT1aRfl/fl 
x LDLR-/- mice were fed Western diet for a total of 5 weeks beginning at 8-10 
weeks of age.  After the first week on diet, mice were implanted with Alzet 28-day 
osomotic mini-pumps (Model 2004, DURECT Corporation, Cupertino, CA) filled 
with either saline or AngII (Sigma, St. Louis, MO) delivered at a rate of 1,000 
ng/kg/min.  Mini-pumps were implanted subcutaneously under a low dose of 
ketamine/xylazine anesthesia and bupivacaine was used as a local anesthetic 
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over the stapled closure site.  Anesthetized mice were exsanguinated  at the end 
of the 28-day infusion after a 4-hour fast for plasma and tissue harvest. 
3.3.2 In vivo measurements 
 Body composition measurements were performed monthly using NMR 
spectroscopy (EchoMRI).  Blood pressure was measured non-invasively by the 
tail-cuff method (Visitech Systems, Inc., Apex, NC).  Blood pressure 
measurements were performed at the end of each month during the LDLR-/- time 
course diet study, during the week prior to and the third week during AngII 
infusion in the AngII-induced AAA study.  Preliminary measurements were taken 
each day prior to data collection and the criteria for inclusion required at least 5 
(out of 10) successful measurements per day with less than 30% standard 
deviation.  For the AngII infusion study, ultrasound images of the abdominal aorta 
above the renal branches were obtained for quantification of lumen diameters at 
day 0, 14, and 28 of AngII infusion (Vevo 2100, VisualSonics, Toronto, Canada).   
3.3.3 Plasma and serum measurements 
 Plasma renin concentrations were measured by incubating plasma (8 µl) 
with exogenous AGT (25 nM) in the presence of ACE inhibitors and then 
angiotensin I (AngI) production was quantified by radioimmunoassay (DiaSorin, 
Via Crescentino, Italy).  Plasma AGT levels were measured with the Mouse Total 
Angiotensinogen Assay Kit (Immuno-Biological Laboratories Co., Gunma, 
Japan).  Total cholesterol and triglyceride (LabAssay) levels were quantified with 
respective kits from Wako Diagnostics (Richmond, VA).  
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3.3.4 Assessment of AAAs in AngII-infused mice 
A greater than 50% increase in lumen diameter, measured by ultrasound, 
was one parameter used to determine AAA incidence.  Peri-aortic fat was 
carefully collected and placed into RNAlater so that cleaned aortic tissue could 
be placed in 10% w/v formalin.  Maximal external suprarenal aortic diameters 
were obtained from cleaned aortas using NIS Elements imaging software.  
Presence and severity of AAA pathology were also graded by two individuals 
blinded to the genotype of the mice based on the Type I – Type IV grading 
system previously described (64).  AAA pathology was only assessed in mice 
exhibiting at least 2 signs of successful AngII infusion (defective osmotic pumps 
can compromise effective AngII delivery), indicated by low plasma renin 
concentrations, increased blood pressure, or visual AAA pathology.   
3.3.5 Quantification of atherosclerotic lesion area 
 After fixation in 10% formalin, aortas were cut longitudinally to expose the 
intimal surface and pinned for en face analysis.  The arch and thoracic regions 
were determined (the arch area encompassed the ascending aorta down to 3 
mm below the left subclavian artery; the thoracic area began at this point and 
extended 9 mm down the descending thoracic aorta) and lesion areas were 
expressed as a percent of the total area for each region.  Lesion areas were 
calculated using NIS Elements software (Nikon Instruments, Inc., Tokyo, Japan). 
 100 
 
3.3.6 Quantification of mRNA abundance 
 RNA was isolated using either Promega Total RNA Isolation System 
(Promega, Madison, WI) or Qiagen Lipid RNeasy kit (Qiagen, Valencia, CA).  
Reverse transcription reactions were set up with 0.4 µg RNA using qScript cDNA 
SuperMix and real-time PCR reactions were performed with PerfeCTa SYBR 
Green FastMix using 2 ng of cDNA template (Quanta Biosciences, Gaithersburg, 
MD).  Standard curves were generated from ten-fold dilutions of concentrated 
cDNA from tissues known to express the gene of interest and this standard curve 
was used to calculate the starting quantity of template from the given Ct values.  
Data are expressed as the ratio of the gene of interest to the starting quantity of 
the housekeeping gene 18S.  
3.3.7 Determination of adipocyte size 
 Sections of formalin (10% w/v) fixed pieces of retroperitoneal or 
subcutaneous adipose tissue were stained with hematoxylin and eosin (H&E).  
Images of slides were obtained at 10x magnification and using the “detect 
edges”, image threshold, and object count features of NIS Elements software 
(Nikon, Instruments, Inc., Tokyo, Japan), the area of each adipocyte within a 700 
x 700 µm measurement frame was quantified.  Three measurement frames on 
each slide and 3 slides per genotype group were analyzed for morphology.   
3.3.8 Lipolysis assay  
 Epididymal adipose tissue explants (25 mg) were collected from saline-
infused AT1aRfl/fl x LDLR-/- and AT1aRaP2 x LDLR-/- mice fed Western diet for a 
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total of 5 weeks.  Filtered Kreb’s buffer supplemented with fatty-acid free bovine 
serum albumin (2% BSA) was used for washes and treatment dilutions.  Explants 
were washed 3 times and incubated in a 48-well plate containing various 
treatments (0.5 mL) for a total of 5 hours, though “conditioned media” was 
sampled at 30, 90, and 180 minutes then frozen at -20⁰C.  Treatments included 
10 µM AngII (Sigma, St. Louis, MO), 1 µM losartan (Merck), 1 µM isoproterenol 
(Sigma, St. Louis, MO), or combinations of AngII with losartan or isoproterenol at 
these same concentrations (for combination treatments, explants were pre-
treated in losartan or isoproterenol for 15 minutes prior to addition of AngII).   At 
the end of the 5-hour incubation, glycerol concentrations were measured from 
“conditioned media” (15 µL) using a colorimetric assay (Cayman Chemical Co., 
Ann Arbor, MI).   Explants were also collected for protein extraction and 
quantification using the Pierce©BCA Assay (Thermo Scientific, Rockford, IL).  
Data are expressed as the ratio of glycerol to protein concentrations.   
3.3.9 Statistical analyses 
 Data from the LDLR-/- time course study were analyzed by two way 
ANOVA to compare the different diet and duration groups.  Student’s t-tests were 
used for comparisons between the two genotypes, except in instances where 
treatment (saline or AngII infusion) was an additional factor, in which case two 
way ANOVA was used to compare the 4 treatment/genotype groups.  Post-hoc 
analysis of two was ANOVA results used the Holm Sidak test.  If normality or 
equal variance tests failed, simple transforms were performed or the non-
parametric Kruskal-Wallis test was used with Dunn’s post-hoc analysis.  Data are 
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represented as mean ± SEM  and statistical significance was  defined as P < 
0.05. 
 103 
 
3.4 Results  
3.4.1 Diets modulate AT1aR expression in peri-aortic fat 
 Our first goal was to characterize changes in expression of RAS 
components in response to hypercholesterolemia, particularly in peri-aortic fat 
(PAF), to better understand how PAF may contribute to AngII-induced vascular 
diseases.  Chow-fed LDLR-/- mice gained little weight over the 3 month duration 
of the study (Figure 3.1A) In contrast, HF- and Western-fed mice exhibited 
significant elevations in body weight beginning at 2 and 3 weeks, respectively, 
and gained similar amounts of weight (Figure 3.1A).  Fat mass increased in mice 
fed all diets after 3 months (Figure 3.1B, P < 0.001), though was significantly 
increased by Western and HF diets compared to chow (P< 0.001).  Importantly, 
although Western- and HF-fed mice achieved similar levels of weight gain 
(Figure 3.1A), only Western-fed mice exhibited significant hypercholesterolemia 
(Figure 3.1C, P < 0.05) and triglyceridemia (Figure 3.1D, P < 0.05). 
There were trends for age-dependent downregulation of AT1aR mRNA 
abundance in thoracic PAF, while age increased AT1aR mRNA abundance in 
abdominal peri-aortic fat of chow-fed mice (Figure 3.2A,B).  However, these 
effects were not statistically significant.  Interestingly, when mice were fed chow 
or HF diets, the age-dependent downregulation of AT1aR mRNA abundance in 
thoracic PAF was significant.  AT1aR mRNA abundance was significantly 
decreased by the same extent in  thoracic PAF of  2 or 3 month Western or HF 
diet-fed mice compared to 1 month  (Figure 3.2A).  In contrast, AT1aR mRNA 
abundance in abdominal PAF was strikingly reduced by both Western and HF 
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diets compared to mice fed chow after 3 months of respective diets (Figure 
3.2B).  Also, Western diet had a more robust effect to increase AT1aR mRNA 
abundance in abdominal PAF compared to HF-feeding at 1 and 2 months.  In 
contrast to AT1aR expression, AGT mRNA abundance in PAF (Figure 3.2C,D) 
was not regulated by any of the diets at any time point.  In liver, AGT mRNA 
abundance was modestly elevated by HF diet at 2 and 3 months, and was 
decreased by Western diet at 3 months (Figure 3.2F, P < 0.05).   
Plasma renin and AGT concentrations were used as stable and reliable 
indicators of systemic RAS activation.  Both hypercholesterolemia (65) and HF 
diets (100) have been shown to increase circulating angiotensin peptide levels, 
indicating an activated RAS.  Hypercholesterolemia robustly increased plasma 
renin concentrations after 3 months of diet (Figure 3.3A, P < 0.05), while the HF 
diet increased circulating AGT levels after 3 months (Figure 3.3B, P < 0.05), 
indicating different mechanisms of RAS activation by these diets. 
3.4.2 Adipocyte-AT1aR deficiency has no effect on diet-induced 
atherosclerosis 
 To determine the role for endogenous AngII acting at the adipocyte 
AT1aR in diet-induced atherosclerosis, AT1aRfl/fl x LDLR-/- and AT1aRaP2 x 
LDLR-/- mice were fed Western diet for 3 months beginning at 8 weeks of age.  
No differences in body weight, percent fat mass, or percent lean mass were 
observed between the two groups (Figure 3.4A,B).  Serum cholesterol and 
triglyceride levels were also not significantly different between AngII-infused 
AT1aRfl/fl and AT1aRaP2 mice (Figure 3.4C,D).  Atherosclerotic lesion areas were 
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quantified both on the arch and thoracic regions of the aorta.  Adipocyte-AT1aR 
deficiency had no effect on the development of atherosclerosis in either region of 
the aorta (Figure 3.4E,F). 
3.4.3 Adipocyte-AT1aR deficiency does not influence AngII-induced AAAs and 
atherosclerosis 
 LDLR-/- mice fed Western diet for 1 week prior to and during subsequent 4 
weeks of AngII infusion exhibit increases in atherosclerotic lesion development 
and AAA formation.  To investigate the effect of adipocyte-AT1aR deficiency on 
these AngII-induced pathologies, we infused AT1aRfl/fl x LDLR-/- and AT1aRaP2 x 
LDLR-/- mice with AngII for 1 month.  Similar to observations  in diet-induced 
atherosclerosis, there was no effect of adipocyte-AT1aR deficiency on percent 
lesion area in either the aortic arch or thoracic regions of AngII-infused mice 
(Figure 3.5A,B).  Additionally, adipocyte AT1aR deficiency had no effect was on 
AngII-induced AAAs, as measured by abdominal aortic lumen and external 
diameters (Figure 3.5C,D).  
3.4.4 Modest adipocyte hypertrophy is caused by adipocyte-AT1aR deficiency 
in retroperitoneal adipose 
 Adipocyte hypertrophy was observed in lean (LF-fed or AngII-infused 
chow fed) AT1aRaP2 mice, so we examined adipocyte morphology of AngII 
infused mice fed a Western diet.  AngII-infused AT1aRaP2 x LDLR-/- mice did 
exhibit adipocyte hypertrophy in retroperitoneal fat (RPF), though the effect was 
modest and differences in mean adipocyte size or cell number did not reach 
statistical significance (Figure 3.6 A-F).  Body weight was not affected by 
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adipocyte-AT1aR deficiency in LDLR-/- mice infused with saline or AngII infusion; 
however, AngII infusion did reduce body weight and adipose tissue masses to a 
greater extent in AT1aRaP2 x LDLR-/- mice compared to AT1aRfl/fl mice (Table 
3.2).  Adipose tissue lipolysis was examined as a potential mechanism 
contributing to adipocyte hypertrophy and increased fat mass, however glycerol 
production from adipose explants was unaffected by AngII, losartan, or by 
adipocyte-AT1aR deficiency (Figure 3.6G).  However, isoproterenol significantly 
increase adipocyte lipolysis, which was not influenced by losartan or AngII 
(Figure 3.6G).    
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3.5 Discussion 
 AngII is known to promote various vascular pathologies through the 
AT1aR in hypercholesterolemic mice, though the cell types mediating these 
effects are unknown.  We proposed that AngII acts through adipocyte AT1aRs to 
promote the development of vascular diseases.  Despite investigating models of 
both endogenous and exogenously administered AngII, we found no role for the 
adipocyte AT1aR in the development of atherosclerosis or AAAs.  Interestingly, 
adipocyte-AT1aR deficiency did result in modest adipocyte hypertrophy in AngII-
infused mice.  These effects were not due to changes in adipose tissue lipolysis 
and are possibly due to previously identified reductions of adipocyte 
differentiation in mice lacking adipocyte AT1aRs. 
The effects of hypercholesterolemia and HF diet on mRNA abundance of 
AT1aR in adipose tissue were characterized to understand dietary manipulation 
of this receptor as a potential contributor to vascular diseases.  In this study, 
even though both diets induced weight gain, only LDLR-/- mice fed Western diet 
exhibited significant elevations in serum cholesterol and triglyceride levels.  The 
purpose of using these diets was to determine whether hypercholesterolemia or 
high fat feeding was a better stimulus to activate the adipose RAS, however this 
study is limited by the inability to distinguish whether differential effects of these 
diets were due to the induction of hypercholesterolemia by Western diet, the 
different amounts of fat in the diets, or the different sources of dietary fat.  
Hypercholesterolemia has been previously reported to upregulate AT1aR 
expression in vascular tissues (181-182), though the effects on adipocytes are 
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unknown.  In mice fed Western diet for 1 month, we also observed an increase in 
AT1aR mRNA abundance in abdominal, but not thoracic PAF compared to chow-
fed controls.  However, in contrast to previously observed effects of 
hypercholesterolemia to increase vascular wall cell AT1aR expression, in this 
study we observed a striking reduction in AT1aR mRNA abundance following 3 
months of Western or HF diet feeding in thoracic and abdominal PAF.  Effects of 
these diets to reduce AT1aR mRNA abundance were more pronounced in 
abdominal than thoracic PAF.  This may relate to the types of adipocytes in 
adipose tissue surrounding these different aortic regions (203).  Brown 
adipocytes are localized to thoracic PAF, while a mixture of white and brown 
adipocytes surround abdominal PAF.  Differences in the type of adipocytes in 
these different aortic regions may have influenced regulation of AT1aR 
expression by Western and/or HF diets.  However, since both diets resulted in a 
marked reduction in AT1aR mRNA abundance in PAF at 3 months, then 
differences in dietary composition or type of adipocytes most likely did not 
contribute to diet-induced decreases in AT1aR expression. 
 Circulating angiotensin peptides are increased in the setting of chronic 
Western feeding to LDLR-/- (65) mice as well as in C57BL/6 mice fed a HF diet 
for 4 months (100).  Results from our study indicate that RAS activation in these 
conditions occur through distinct mechanisms.  Plasma renin concentrations 
were significantly elevated after consumption of the Western diet for 3 months.  
These results suggest that increased renin concentrations in plasma most likely 
contributed to previously observed elevations in plasma AngII concentrations in 
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Western diet-fed LDLR-/- mice (65).  However, a well known facet of the RAS in 
mice is the existence of negative feedback regulation of renin production in 
response to AngII.  Thus, it is unclear why elevated plasma AngII concentrations 
in LDLR-/- mice fed the Western Diet (65) did not result in negative feedback-
mediated reductions in plasma renin concentrations.  Indeed, following 1 month 
of Western or HF diet-feeding, mice exhibited reductions in plasma renin 
concentrations suggestive of increased levels of circulating AngII.  Additional 
studies, including quantification of plasma AngII concentrations (this was not 
performed in this study due to insufficient volumes of mouse plasma) are 
required to determine mechanisms for high plasma renin concentrations in 3 
month Western diet-fed LDLR-/- mice.  However, since whole body AT1aR 
deficiency markedly reduces atherosclerosis in LDLR-/- mice (65), then it is 
unlikely that these mice exhibit low activity of the systemic RAS.  In contrast to 
the Western diet, consumption of the HF diet increased plasma AGT levels, 
demonstrating an effect of this diet to increase the amount of precursor to 
promote the conversion to AngII.  Indeed, chronic consumption of this HF diet in 
C57BL/6 mice is associated with robust elevations in circulating concentrations of 
AngII (100, 258).  Although AGT mRNA abundance in adipose tissue was not 
regulated by any of the diets, increased fat mass with HF diet along with 
increased liver AGT expression are likely contributors to HF-induced elevations 
in circulating AngII.  In contrast to previous findings (65), we did not observe 
elevations in plasma AGT concentrations in Western diet-fed LDLR-/- mice.  This 
discrepancy is most likely due to different methods for measuring plasma AGT 
 110 
 
(Western blot versus ELISA in our study) or the different controls used (LDLR+/+ 
vs chow-fed LDLR-/- mice in our study).  
    Chronic feeding of Western diet to LDLR-/- over a period of 3 months 
results in the development of atherosclerotic lesions in the aorta and adipocyte-
AT1aR deficiency was not protective against lesion formation in this model.  
While these findings may be due to the downregulation of AT1aR expression in 
PAF surrounding the thoracic region of the aorta observed in the LDLR-/- time 
course study, this is unlikely because receptor expression was high through the 
first 2 months of diet feeding, which is the time frame during which the initial 
phases of lesion formation begin.  Evidence for a direct role of adipocytes or 
adipocyte-derived factors in the development of atherosclerotic plaques 
continues to emerge as more groups characterize the proinflammatory 
phenotype of perivascular adipose (51, 109, 188).  One approach to studying the 
direct influence of adipose tissue in atherosclerosis is the transplantation of non-
perivascular fat directly adjacent to the carotid artery in ApoE-/- mice susceptible 
to atherosclerosis (188-189).  While results from these studies clearly 
demonstrate that inflammation in transplanted visceral adipose tissue serves as 
a causative factor in lesion formation, it remains unclear whether inflammation of 
endogenous perivascular adipose depots is sufficient to contribute to this 
disease.  Our model of adipocyte-AT1aR deficiency has the advantage of 
examining the role of endogenous adipose tissue in vascular diseases.  
Adipocyte-AT1aR deficiency, however, did not have an effect on atherosclerosis 
in LDLR-/- mice fed Western diet for 3 months, indicating that this receptor has no 
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role in adipose tissue inflammation.  Other models of adipocyte-specific 
deficiency of proatherogenic adipocyte factors are required to delineate the role 
of adipocytes in atherosclerosis. 
 Infusion of AngII for 4 weeks in mice fed Western diet for a total of 5 
weeks is a well-established model of AAA formation in LDLR-/- mice (62).  
Deficiency of AT1aRs in adipocytes had no effect on the development of AngII-
induced AAAs.  Previous work from our lab found that HF diet and the 
development of obesity promotes AAA formation in normocholesterolemic 
C57BL/6 mice infused with AngII (203).  Police, et al. demonstrated increased 
MCP-1 secretion from and macrophage infiltration in PAF surrounding the 
abdominal region of aorta where AAAs form, leading us to hypothesize that AngII 
may be acting at the adipocyte AT1aR to upregulate MCP-1 production, thus 
promoting macrophage infiltration and disease progression.  Instead of using the 
obesity model from the work of Police, et al. (C57Bl/6 mice fed HF diet for 4 
months with AngII infusion during the final month of diet), we chose to use a 
mouse model of adipocyte-AT1aR deficiency in LDLR-/- mice fed Western diet.  
This model allowed us to study the development of both atherosclerosis and 
AAAs, and compare our results to previous work investigating cell types involved 
in AngII-induced vascular pathologies which have been performed on 
hypercholesterolemic LDLR-/- or ApoE-/- mice.  The lack of an effect of adipocyte-
AT1aR deficiency on vascular disease in our model, however, suggests that the 
obesity or ApoE-/- models may be more effective in elucidating the role of 
adipocyte AT1aRs.  While our results demonstrate that 3 months of HF diet 
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tended to reduce PAF mRNA abundance of AT1aR and AGT in LDLR-/- mice, this 
may not be the case in 4 month HF-fed C57BL/6 infused with AngII for 1 month.  
ApoE deficiency presents another potential model to study this receptor because 
hypercholesterolemia can be achieved in the absence of Western diet, avoiding 
possible diet-induced regulation of adipose RAS components.  Future studies 
may make use of these models to further examine the role of adipocyte AT1aRs 
in the development of atherosclerosis and AAAs. 
AngII infusion in several models has been reported to induce weight loss 
(34, 37, 77, 202) and our study confirms this in LDLR-/- mice fed Western diet for 
5 weeks.  Some of these studies suggest that AngII may regulate adipose tissue 
lipolysis, however reports are conflicting.  To determine if AngII regulates lipolysis 
through the adipocyte AT1aR, we measured glycerol production from epididymal 
adipose explants from saline-infused AT1aRfl/fl x LDLR-/- and AT1aRaP2 x LDLR-/- 
mice in the presence or absence of AngII, losartan, or the β-adrenergic agonist 
isoproterenol.  Incubation with AngII, losartan, or a combination of both had no 
effect on glycerol production in either genotype, demonstrating that AngII does 
not directly regulate lipolysis through the AT1aR.  Glycerol production was 
dramatically increased when explants were exposed to isoproterenol 
independent of AngII co-incubation, suggesting that AngII does not modulate the 
lipolytic response to sympathetic stimulation.  It is possible that AT1aR activation 
by AngII regulates the transcription of genes involved in lipolysis and the 5-hour 
incubation of explants throughout the lipolysis assay was insufficient for these 
changes to manifest and glycerol production to be affected.   
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 Adipocyte-AT1aR deficiency was found to reduce adipocyte differentiation 
from isolated preadipocytes and cause striking adipocyte hypertrophy in lean but 
not obese (Chapter 2).  These findings led us to quantify adipocyte size in AngII-
infused mice fed Western diet, revealing modest but not significant adipocyte 
hypertrophy in RPF of AT1aRaP2 x LDLR-/- mice.  Interestingly, the effect of 
adipocyte-AT1aR deficiency to cause adipocyte hypertrophy seems to positively 
correlate with the leanness of the mice, with the most dramatic effects observed 
LF-fed mice and a lack of effect in obese mice.  Obesity and HF-feeding are 
associated with inhibited adipocyte differentiation, suggesting that adipocyte 
differentiation is partially inhibited in Western fed mice (possibly due to the 
shorter study duration or slightly lower fat content of the diet compared to HF) 
resulting in modest adipocyte hypertrophy. 
 Overall the results from these studies confirm that adipocyte-AT1aR 
deficiency confers no protection against diet- or AngII-induced vascular diseases, 
suggesting that other cell types or synergistic effects between various cell types 
are responsible for the effects of AngII through the AT1aR.  These studies 
confirm previous reports that a diet high in fat limits the regulation of adipocyte 
size by adipocyte-AT1aR deficiency.    
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Table 3.1 Composition of diets. 
 Standard chow Western High Fat 
Source Harlan Teklad Global 
18% Protein Rodent 
Diet, 2018 
Harlan Teklad 
Custom Research 
Diet, 88137 
Research Diets, Inc. 
D12492 
Kcal/g 3.1 4.5 5.24 
Protein (% of total 
kcal) 
24 15.2 20 
Carbohydrate (% of 
total kcal) 
58 42.7 20 
Fat (% of total kcal) 18 42 60 
Fat sources Soybean oil Milkfat Lard (91% of fat 
kcal), soybean oil 
(9% of fat kcal) 
Cholesterol -- 0.2% (0.15% added, 
0.5% from milkfat) 
0.03%  
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Table 3.2 Body and tissue weights in saline or AngII-infused AT1aRfl/fl x 
LDLR-/- or AT1aRaP2 x LDLR-/- mice.  
 Saline  AngII  
 AT1aRfl/fl x 
LDLR-/- 
AT1aRaP2 x 
LDLR-/- 
AT1aRfl/fl x 
LDLR-/- 
AT1aRaP2 x 
LDLR-/- 
n 6 7 19 24 
Final body weight 
(g) 
33.2 ± 1.6  30.7 ± 0.9 28.3 ± 0.5* 29.4 ± 0.6 
Liver (g) 1.66 ± 0.18 1.48 ± 0.06 1.41 ± 0.05 1.46 ± 0.05 
Kidney (g) 0.42 ± 0.04 0.37 ± 0.03 0.31 ± 0.01* 0.031 ± 0.01* 
Epididymal fat (g) 1.10 ± 0.17 1.14 ± 0.09 0.84 ± 0.07 1.02 ± 0.06 
Retroperitoneal fat 
(g) 
0.40 ± 0.07 0.41 ± 0.04 0.28 ± 0.03* 0.35 ± 0.02 
Subcutaneous fat 
(g) 
0.61 ± 0.10 0.63 ± 0.06 0.41 ± 0.03* 0.50 ± 0.04 
BAT (g) 0.16 ± 0.02 0.17 ± 0.02 0.13 ± 0.01 0.15 ± 0.01 
Data are mean ± SEM. *P < 0.05 compared to saline within genotype 
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Figure 3.1 Characteristics of LDLR-/- mice fed chow, Western, or HF diets for 
1-3 months. (A) Body weights through the duration of the study. Compared to 
chow-fed mice, body weights of HF- and Western-fed mice were significantly 
higher beginning at week 2 (*, P < 0.05) and 3 (**, P < 0.05), respectively. (B) Mice 
of all groups had significantly increased % fat mass and reduced % lean mass 
after consumption of diets for 3 months (*, P < 0.001 compared to baseline) and 
mice fed HF or Western diet had greater fat mass/ reduced lean mass (†, P < 
0.001 compared to chow after 3 months).  Serum cholesterol (C) and trigycerides 
(D) were elevated in Western-fed mice compared to chow at each time point (*, P 
< 0.05).  Data are represented as mean ± SEM from 6-8 mice/group. 
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Figure 3.2 mRNA abundance of AT1aR and AGT in peri-aortic fat and liver.  
AT1aR mRNA abundance was reduced in thoracic PAF (A) after 2 and 3 months 
of Western or HF diet consumption (*, P < 0.05 compared to 1 month within diet) 
AT1aR mRNA abundance in abdominal PAF(B) was suppressed in Western- and 
HF-fed mice (*, P < 0.05 compared to chow within time group; **, P < 0.05 
compared to mice fed Western for 1 month; and ***, P < 0.05 compared to mice 
fed Western for 3 months).  AGT mRNA abundance in thoracic (C) and 
abdominal PAF (D) were unaffected by diet.  Liver AT1aR mRNA abundance (E) 
was unchanged, however AGT was modestly increased by HF diet and 
suppressed after 3 months of Western diet consumption (*, P < 0.05 compared  
to chow within month).  Data are represented as mean ± SEM from 6-8 
mice/group.  
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Figure 3.3 Plasma renin and AGT concentrations in LDLR-/- mice fed chow, 
Western or HF diets.  A, Plasma renin concentrations were suppressed by 
chow diet and elevated by Western diet consumption after 3 months (*, P < 0.05 
compared to 1 month within diet; **, P < 0.05 compared to chow within month). 
B, Plasma angiotensinogen levels were elevated by consumption of HF diets 
compared to chow or Western diets (**, P < 0.001) and compared to 1 month of 
HF diet consumption (*, P < 0.05). Data are represented as mean ± SEM from 6-
8 mice/group. 
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Figure 3.4 Adipocyte-AT1aR deficiency has no effect on diet-induced 
atherosclerosis in LDLR-/- mice.  A, Body weights of mice fed Western diet for 
3 months. B, Percent fat mass was increased and lean mass decreased after 3 
months of diet consumption (*, P < 0.05). Serum cholesterol (C) and triglycerides 
(D) were unaffected by adipocyte AT1aR deficiency.  Lesion areas were 
calculated as a percentage of total area in both the aortic arch (E) and thoracic 
aorta (F). Data are represented as mean ± SEM from 10-12 mice/group. 
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Figure 3.5 Adipocyte-AT1aR deficiency has no effect on the development 
of atherosclerosis or AAAs in AngII-infused mice. A, Lesion areas were 
calculated as a percentage of total area in both the aortic arch (A) and thoracic 
aorta (B).  C, Lumen diameters were quantified from ultrasound images taken 
prior to, 14 days and 28 days into AngII infusion.  D, Maximal external diameters 
were measured from aortas cleaned of peri-adventitial tissue. 
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Figure 3.6 Adipocyte-AT1aR deficiency causes modest adipocyte 
hypertrophy in retroperitoneal fat (RPF) of LDLR-/- mice.  Frequency 
distributions of adipocyte size in RPF of mice infused with saline (A) or AngII (B).  
Representative images of H&E stained RPF from mice infused with saline (C) or 
AngII (D).  Mean adipocyte size (E) and cell numbers per measurement frame (F) 
were unaffected by AngII infusion or adipocyte AT1aR deficiency.  G, Production 
of glycerol from epididymal adipose explants was used to quantify lipolysis in 
response to incubation with AngII, losartan (Los), isoproterenol (Iso), as well as 
combinations of AngII with Los or Iso (*, P < 0.001, compared to vehicle). 
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SECTION IV: GENERAL DISCUSSION 
4.1 Summary 
 The purpose of the studies described in this dissertation was to test 
the hypothesis that AngII regulates adipose tissue development, function, and 
inflammation through the adipocyte AT1aR.  A mouse model of adipocyte-AT1aR 
deficiency was developed using the Cre/LoxP system to investigate these 
potential roles of the adipocyte-AT1aR in lean, obese, and hypercholesterolemic 
mice.  AT1aRaP2 mice fed chow diet for one year exhibited no changes in body 
weight or fat mass.  To stress these mice, we infused saline or AngII for 28 days, 
which led to modest weight loss in AngII infused mice of both genotypes.  
However fat mass and glucose tolerance were unchanged.  Analysis of adipocyte 
morphology revealed modest adipocyte hypertrophy in saline-infused AT1aRaP2 
mice.  AngII infusion caused a reduction in adipocyte size in AT1aRfl/fl controls, 
and, surprisingly, AT1aRaP2 mice were protected from this effect. 
Adipocyte-AT1aR deficiency was also studied in mice fed LF or HF diets 
for a period of 16 weeks.  Lack of AT1aRs had no effect on the body weight, fat 
mass, glucose intolerance, or blood pressure on either diet, however all mice fed 
HF diet had significant elevations in all of these parameters.  Similar to AngII-
infused mice fed chow diet, LF-fed AT1aRaP2 mice displayed striking adipocyte 
hypertrophy compared to AT1aRfl/fl mice.  This phenotype, however, was lacking 
in AT1aRaP2 HF-fed mice.   
   The adipocyte differentiation capacity of preadipocytes isolated from 
AT1aRaP2 mice was reduced, possibly due to downregulation of PPARγ, 
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providing a potential mechanism of adipocyte hypertrophy in which the remaining 
differentiated adipocytes in AT1aRaP2 mice accrue more lipid over time.  The 
positive regulation of adipocyte differentiation and PPARγ mRNA abundance by 
AngII was also confirmed in 3T3-L1 cells.   
 The contribution of adipocyte-AT1aRs to vascular disease was also 
explored because while AngII is known to promote these diseases through the 
AT1aR, the cell type mediating these pathological effects remains unknown.  
Adipocyte-AT1aR deficiency in LDLR-/- mice fed Western diet for 3 months had 
no effect on the formation of atherosclerotic lesions in the arch or thoracic 
regions of the aorta.  In a model of AngII-induced AAAs, adipocyte-AT1aR 
deficiency also had no effect on atherosclerosis or AAAs.  Like LF-fed and AngII-
infused chow-fed AT1aRaP2 mice, adipocyte hypertrophy was also observed in 
AT1aRaP2 x LDLR-/- , however the effect was more modest which may relate to 
the effects of diets high in fat to suppress adipocyte differentiation.  These 
changes in adipocyte size and fat mass occurred independent of any changes in 
lipolysis. 
 Overall, the results of these studies suggest that the primary role of the 
adipocyte AT1aR is to promote adipocyte differentiation.  The in vivo 
manifestations of this effect appear to be a regulation of adipocyte size in lean, 
but not obese, mice.  It is unclear why AT1aRaP2 x LDLR-/- mice fed Western diet 
for 5 weeks with AngII infusion display moderate protection from AngII-induced 
reductions in fat mass, especially when the effects on adipocyte morphology are 
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modest, however future studies including measurements of food intake and 
energy expenditure may resolve this matter. 
4.2 The interplay between the adipose RAS and metabolic syndrome: Insights 
from adipocyte-AT1aR deficiency 
4.2.1 Regulation of the adipose RAS in obesity 
 AngII has been suggested to participate in a feed-forward loop to promote 
further AngII production by increasing the expression of AGT in liver (111) and 
adipose (154).  A study from our group by Lu, et al. demonstrated that chronic 
AngII infusion increased mRNA abundance of AGT and AT1R in adipose tissue, 
however this regulation was absent in liver (154).  Furthermore, increased AGT 
expression in adipose was attributed to AT1aR-mediated effects because 
losartan reduced increased expression in AT2R deficient mice.  Obesity is 
associated with RAS activation and high levels of circulating AGT and AngII 
levels (100, 268), which may be due in part to increased AGT production by 
adipose tissue.  It has been unclear, however, whether increased adipose AGT 
secretion in obesity is due to the AT1aR-mediated positive feed-forward loop in 
adipose tissue described by Lu, et al.  To address this possibility, we measured 
plasma AGT levels in HF-fed AT1aRfl/fl and AT1aRaP2 mice, and while adipocyte-
AT1aR deficiency had no effect on plasma AGT concentrations, we did confirm 
that circulating AGT levels are increased with HF diet.  AGT mRNA abundance 
was quantified in liver to determine if liver production of AGT was increased to 
compensate for possible reductions in adipose tissue, but liver and adipose AGT 
expression were unaffected by adipocyte-AT1aR deficiency.  These results 
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indicate that AGT production in adipocytes is not regulated by a direct effect of 
AngII at adipocyte AT1aR.  Increased circulating AGT despite reduced mRNA 
abundance in adipose is likely due to the dramatic increases in fat mass with 
obesity that result in overall increased levels of adipose-derived AGT.  
4.2.2 Contribution of the adipose RAS to metabolic syndrome 
 Most of the obesity-related disorders associated with the metabolic 
syndrome (Table 1.3) were unaffected by adipocyte-AT1aR deficiency, including 
high blood pressure, glucose intolerance, and atherogenic dyslipidemias.  
Although blood pressure was elevated in mice fed a HF diet or infused with 
AngII, adipocyte-AT1aR deficiency did not result in lower blood pressures in 
chow, LF, HF, or Western-fed mice.  Glucose tolerance was measured in chow-
fed mice, LF-, and HF-fed mice without any changes in AT1aRaP2 mice compared 
to controls.  Total cholesterol and triglyceride serum concentrations were not 
influenced by adipocyte-AT1aR deficiency in mice fed Western diet for 3 months 
or for 5 weeks with concurrent 28-day AngII infusion.  Deficiency of adipocyte 
AT1aRs also did not impact weight gain in mice chronically fed HF or Western 
diets, however unexpected elevations in body weight and fat mass were 
observed in AngII-infused mice fed Western diet for 5 weeks.  These results 
would indicate that adipocyte-AT1aR deficiency has no protective role in the 
development of the various elements of metabolic syndrome.   
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4.3 Limitations of the model of adipocyte-AT1aR deficiency 
4.3.1 Non-specific reductions in AT1aR mRNA abundance 
 The model of adipocyte-AT1aR deficiency used in these studies was 
developed using the Cre/LoxP system, in which the only coding exon of the 
AT1aR gene, exon 3, was flanked by LoxP sites and mice were bred to 
transgenic mice expressing Cre recombinase driven by the aP2 promoter.  The 
aP2 protein, also known as fatty-acid binding protein 4 (Fabp4), was originally 
described as adipocyte-specific and used by several groups to reduce gene 
expression in adipocytes.  However, as more of these models have been made, 
it has become clear that the aP2 gene is also expressed in other tissues, such as 
cardiomyocytes.  Indeed, mRNA abundance of AT1aR in AT1aRaP2 mice was 
reduced significantly in the heart.  To better understand the non-specific 
expression of Cre recombinase driven by the aP2 promoter, we bred AT1aRaP2 
mice to ROSA26 mice, which contain a stop codon flanked by LoxP sites within 
the β-galactosidase gene (241).  In tissues where Cre recombinase is expressed, 
the stop codon is removed, active β-galactosidase is produced, and activity of 
this enzyme can be detected through X-gal staining as a marker of Cre 
recombinase expression.  Several tissues were collected from AT1aRfl/+,aP2 x 
ROSA26+/- (Cre 0/+) mice for X-gal staining and compared to the robust staining 
in brown and white adipose depots, staining in heart tissue was present but faint.  
Moreover, quantification of heart weight to body weight ratios as a measure of 
cardiac hypertrophy, which is AT1aR-mediated (195), revealed no differences 
between AT1aRfl/fl and AT1aRaP2 mice (data not shown).  Additionally, although 
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AngII can have positive chronotropic and inotropic effects (171, 270), there were 
no reductions in heart rate (data not shown) or blood pressure in AT1aRaP2 mice.  
Therefore, these data suggest that the reductions in heart AT1aR mRNA 
abundance were not physiologically relevant.  
4.3.2 Model validation 
 Validating models of cell-specific AT1aR deletion at the protein level is 
difficult due to the lack of a specific AT1aR antibody (212).  AT1aR mRNA 
abundance was quantified in whole adipose tissue lysates, the adipocyte fraction 
of collagenase-digested adipose tissue, as well as in adipocytes differentiation 
from isolated stromal vascular cells, and residual AT1aR mRNA abundance was 
detectable in all of these adipocyte sources from AT1aRaP2 mice.  This may 
reflect sub-optimal efficiency of Cre recombinase enzyme activity at the LoxP 
sites surrounding exon 3 of the AT1aR gene.  Another possibility is that AT1aR 
deficiency regulates transcription factors controlling aP2 promoter activity.  In 
adipocytes differentiated ex vivo from AT1aRaP2 mice, aP2 mRNA abundance 
was reduced (p = 0.052).  If this regulation by AT1aR is at the aP2 promoter, 
then it suggests reduced aP2 promoter activity in response to AT1aR deficiency 
may subsequently reduce the expression of Cre recombinase, thus 
compromising the deletion of AT1aR.  The use of another promoter to drive Cre 
recombinase activity may be one solution to this issue as well as the issue of 
non-specific expression described above.  The adiponectin promoter has recently 
been suggested to be more efficient and specific than the aP2 promoter for 
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adipocyte-specific gene deletion; however studies from our lab using this 
promoter also show reductions in target gene expression in heart. 
4.4 Insights into regulation of adipocyte size and fat mass by AngII 
4.4.1 Differential consequences of adipocyte differentiation in LF- and HF-fed 
mice 
The finding that adipocyte AT1aR deficiency regulates adipocyte 
differentiation and size in vivo could be through several potential mechanisms.  
AngII promotes adipocyte differentiation through the adipocyte AT1aR by 
upregulating PPARγ expression, which is a major regulator of terminal adipocyte 
differentiation from committed preadipocytes (Figure 4.1A).  When stromal 
vascular cells containing preadipocytes were isolated from subcutaneous 
adipose depots of AT1aRfl/fl and AT1aRaP2 mice, preadipocytes from AT1aRaP2 
mice had reduced lipid accumulation and mRNA abundance of PPARγ.  The in 
vivo consequences of reduced adipocyte differentiation are increased lipid 
accumulation and hypertrophy of remaining cells (13).  Interestingly, this resultant 
adipocyte hypertrophy was observed in LF-fed, but not HF-fed, AT1aRaP2 without 
any adverse metabolic consequences. 
 The enhancement of adipocyte differentiation in response to AngII is 
arguably a good thing.  Research by several groups indicates that formation of 
many small adipocytes is less of a health risk than the development of 
hypertrophied adipocytes, which can become inflamed and eventually lead to 
insulin resistance (248).  One potential mechanism linking adipocyte hypertrophy 
to inflammation may be an insufficient angiogenic (40) or an increased fibrotic 
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(104) response to hypoxic conditions experienced by adipocytes, leading to cell 
death and macrophage infiltration (277).  While our finding that mice lacking the 
adipocyte AT1aR experience adipocyte hypertrophy is consistent with a reduced 
capacity for differentiation, the lack of an inflammatory response to this striking 
level of adipocyte hypertrophy is puzzling.  Conceivably, the inflammatory 
response to adipocyte hypertrophy may be mediated by the actions of AngII 
through the AT1aR, in which case deficiency of this receptor would cause 
hypertrophy on the one hand, but simultaneously protect from the inflammatory 
response.  This scenario, however, seems unlikely because it would suggest that 
HF-fed AT1aRaP2 mice should be similarly protected from adipose inflammation 
and related insulin-resistance, however these mice show no improvements in 
glucose or insulin tolerance tests.  Alternatively, our data suggests that lean mice 
were capable of accommodating larger adipocytes without resulting 
inflammation, possibly because the fat pads were still small, such that sufficient 
blood flow was maintained to avoid the hypoxic conditions that lead to adipocyte 
cell death.  Our results indicate that adipocyte hypertrophy alone is insufficient to 
drive the development of obesity-related insulin resistance in otherwise lean 
mice. 
The lack of an effect of adipocyte-AT1aR deficiency on adipocyte size, fat 
mass, and body weight in HF-fed was initially surprising.  However, further 
reading of the literature revealed that adipocyte differentiation may be 
suppressed in the setting of obesity (13, 116, 177, 197).  Specifically, the ability 
of isolated human preadipocytes to successfully differentiate is inversely 
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correlated with BMI (116), waist circumference or percent body fat (197), as well 
as adipocyte size (referring to the size of adipocytes collected after collagenase 
digestion)(101, 116).  In fact, some suggest the initiating event in the 
development of inflamed adipose tissue is the inhibition of adipogenesis and this 
inability to recruit new adipocytes causes the adipocyte hypertrophy that leads to 
obesity-related disorders (14, 101).  These groups distinguish between 
“hyperplastic obesity” (i.e., many small adipocytes) and “hypertrophic obesity” 
(fewer but larger adipocytes) in which adipocyte size, not necessarily BMI, 
determines the metabolic health of adipose tissue.  For instance, one study found 
that women with “hyperplastic obesity” have significantly lower plasma insulin 
and HOMA-IR levels compared to women with similar BMI characterized as 
having “hypertrophic obesity” (13).  Conversely, lean individuals with a genetic 
predisposition for type 2 diabetes have significantly greater adipocyte size 
compared to lean individuals with no predisposition for type 2 diabetes (14).  The 
mechanism through which adipogenesis is inhibited in obesity appears to be a 
defect in the differentiation process and not an inability to recruit stem cells 
because the number of precursor cells actually increases with obesity (116, 155).  
Inhibited differentiation may be due to an inability to suppress canonical anti-
adipogenic WNT signaling pathways because incubation with a WNT inhibitor, 
DKK1, restores differentiation of preadipocytes from obese individuals to 80% 
that of normal weight subjects (101). With all of this in mind, the reason for a lack 
of effect of adipocyte-AT1aR deficiency in HF-fed AT1aRaP2 mice may be the 
general suppression of adipocyte differentiation already occurring in HF-fed mice.  
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These changes in WNT signaling must occur upstream of the effects of AT1aR 
on PPARγ in the signaling cascade determining adipocyte differentiation since 
adipocyte-AT1aR deficiency did not affect HF-induced downregulation of 
differentiation.   
4.4.2 Lipolysis 
 Lipolysis presents another potential mechanism through which AngII may 
regulate adipocyte size.  Lipolysis is the hydrolysis of triglycerides, the primary 
form of lipid storage within adipocytes, into free fatty-acids and glycerol.  If AngII 
stimulated lipolysis, this mobilization of fatty-acids from adipocytes would limit 
adipocyte size and deficiency of adipocyte AT1aRs would have more lipid 
accumulation, which is consistent with our findings.  However, analysis of 
lipolysis from adipose tissue explants determined that AngII did not directly 
stimulate lipolysis.  If anything, there was a modest increase in basal glycerol 
production from AT1aRaP2 explants, which would conflict with the in vivo 
adipocyte size quantifications of hypertrophy in these mice.  An inhibitory effect 
of AngII on lipolysis is consistent with several studies in the literature (31, 96), 
including one specifically showing that this effect in adipocytes is AT1R-mediated 
(95).  However, it is still possible that AngII may participate in long-term 
regulation of lipolytic enzymes that neither our lipolysis explants assay nor the 
microdialysis with AngII infusion experiments of others are designed to elucidate.  
Future work should determine the phosphorylation status and enzyme activity of 
hormone-sensitive lipase and adipose triglyceride lipase with a longer duration of 
AngII incubation to determine if AngII regulates lipolysis through this mechanism. 
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4.5 Future directions  
4.5.1 Other mechanisms through which AngII may regulate adipocyte 
differentiation and size through the AT1aR 
4.5.1.1 Adipocyte aldosterone secretion  
 It has recently been reported that adipocytes are capable of producing not 
only mineralocorticoid-releasing factors (74), but also aldosterone itself (35).  
Briones, et al. reported that stimulation of either 3T3-L1 or isolated adipocytes 
with AngII increases aldosterone secretion as well as aldosterone synthase 
expression (35).  Interestingly, this group also found that incubation of 3T3-L1 
preadipocytes with a specific inhibitor of aldosterone synthase decreased 
adipocyte differentiation significantly (35).  Therefore, AngII may stimulate 
adipocyte aldosterone production which then acts in an autocrine manner at 
adipocyte mineralocorticoid receptors to promote adipocyte differentiation (41).   
4.5.1.2 Conversion of white to brown adipocytes  
 White adipocytes are capable of taking on the phenotypic characteristics 
of brown adipocytes, such as increased mitochondrial biogenesis and 
thermogenesis, through a process commonly referred to as transdifferentiation 
(279).  This process is primarily mediated by the actions of PRDM16 to increase 
the expression of PGC-1α, UCP-1, Cidea, and other proteins that are hallmarks 
of brown adipocytes (233-234) and can be induced by cold exposure (19).  The 
ability of white adipocytes to transdifferentiate presents an interesting mechanism 
through which adipocyte size may be regulated.  The accumulation of brown-like 
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adipocytes in traditionally white adipose depots would likely mobilize fatty acids 
from lipid droplets for oxidation and thermogenesis, reducing lipid accumulation 
in white adipocytes.  Conversely, reducing transdifferentiation may result in 
enlarged adipocytes due to increased lipid accumulation.  In our studies, UCP-1 
expression was reduced significantly in subcutaneous adipose of AT1aRaP2 mice 
fed LF diet (data not shown), and reduced transdifferentiation is consistent with 
the adipocyte hypertrophy observed in these mice.  However, data collected from 
calorimetry chambers during the final week of diet did not reveal any changes in 
oxygen consumption (data not shown) nor was body temperature affected by 
adipocyte-AT1aR deficiency in any of the models in which it was measured 
(chow-fed and Western-fed mice infused with saline/AngII).   Nonetheless, other 
groups are currently investigating the role of adipocyte AT2Rs in the process of 
differentiation and have demonstrated that administration of an AT2R agonist 
increases UCP-1 expression in 3T3-L1 adipocytes (data presented at Gordon 
Research Conference 2012 by Justin Grobe; as yet unpublished).  Further 
investigation is required to determine if white adipocyte transdiffferentiation to 
brown adipocytes plays a role in the adipocyte hypertrophy and increased fat 
mass observed in our models of adipocyte-AT1aR deficiency. 
4.5.2 Further exploration of the adipose RAS 
4.5.2.1 Overactivation of adipose RAS 
 An interesting experiment would be to overexpress the AT1aR in 
adipocytes and study the effects in vivo.  Because the function of adipocyte 
AT1aRs has been poorly understood, overexpressing the receptor to 
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supraphysiological levels would amplify the effects of AngII and perhaps clarify 
what pathways are modulated in adipocytes.  Establishing the signaling 
pathways and physiological processes affected by AngII would guide future 
experiments with adipocyte-AT1aR deficient mice.  According to our studies, 
AngII promotes adipocyte differentiation through the AT1aR, so overexpression 
of this receptor may further increase the number of small adipocytes, though 
other outcomes are also possible.  These effects may also translate into changes 
in fat mass, glucose tolerance, and blood pressure in lean, obese, and 
hyperlipidemic mice.  Adipocyte-AT1aR deficiency led to increased fat mass in 
AngII-infused mice fed Western diet, so overexpression of adipocyte AT1aRs 
may result in weight loss in this model.  No differences in adipocyte size or 
adipose weights were observed in HF-fed AT1aRaP2 mice, possibly due to HF 
diet-induced impairment of adipocyte differentiation, but AT1aR overexpression 
might restore differentiation in these mice.  However, the ability of AT1aR 
overexpression to restore adipocyte differentiation in HF-fed mice would depend 
on the exact nature of the suppression of differentiation and whether or not 
AT1aR signaling can overcome the epigenetic changes brought on by uninhibited 
canonical WNT signaling (101). 
Studies of adipocyte-AGT overexpression have demonstrated modest 
increases in adiposity associated with increased glucose intolerance and adipose 
inflammation in lean mice (134, 291).  These effects were notably absent in HF-
fed mice, similar to our findings with adipocyte-AT1aR deficiency (134).  Although 
the effects of adipocyte-AGT overexpression on adipose tissue were normalized 
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by AT2R deficiency in the AGT-overexpression model (291), there may be a role 
for enhanced AT1aR activation in AT2R knockout mice and it is also possible 
that AT2R deficiency in non-adipocyte cells contributed to these effects.  
Overexpression of AT1aRs in adipocytes would clarify whether any of the effects 
of AGT overexpression were through direct effects of AngII at the adipocyte 
AT1aR, or conversely, adipocyte AGT overexpression could be studied in the 
context of adipocyte AT1aR deficiency.  
 Another method of possibly increasing the activity of the local RAS in 
adipose tissue would be to make a mouse model of adipocyte-specific ACE2 
deficiency.  ACE2 is expressed in adipose tissue and activity of ACE2 in adipose 
is blunted after 4 months of HF diet, possibly contributing to the increased 
circulating levels of angiotensin peptides observed with HF feeding (100).  
Whole-body ACE2 deficiency has been shown to increase atherosclerosis (259).  
It might be particularly interesting to observe the effects of adipocyte-ACE2 
deficiency in models of vascular disease to see if reductions in adipocyte-ACE2 
contribute to the effect observed in whole-body knockouts.  Reduced catabolism 
of AngII by ACE2 might locally increase AngII levels in perivascular adipose 
tissue, enhancing the effects of AngII on adipose tissue macrophages and 
nearby vascular wall cells. 
4.5.2.2 Exploring the role of adipocyte AT2Rs 
 In addition to AT1aRs, adipocytes also express AT2Rs.  Previous studies 
regarding the role of both receptors in the process of adipocyte differentiation 
have been mixed and inconclusive (61, 85, 220-221, 225).  It would be 
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interesting to compare adipocyte deficiency of AT1aRs to that of AT2Rs and 
AT1aR/AT2R double knockouts to further delineate the effects that AngII can 
have on adipocytes. Complications of these studies include the possibilities that 
deficiency of one receptor may change the expression of the other receptors or 
enhance AngII signaling through the remaining receptor.  AT1aRaP2 mice in our 
studies did not show any transcriptional regulation of AT2Rs in response to 
AT1aR deficiency in adipocytes; however the possibility of enhanced signaling 
remains.  The development of mice with adipocyte AT1aR and AT2R deficiency 
would help clarify this point.   
 In AT1aRaP2 mice we observed a reduction in differentiation.  If there is 
spillover of AngII to enhance AT2R signaling in this mice, there are 3 
possibilities: AT2Rs have no effect on differentiation; AT2Rs inhibit 
differentiation; or AT2Rs weakly stimulate differentiation but deficiency of 
AT1aRs has a more powerful effect to reduce differentiation.  AT1aR/AT2RaP2 
mice would help distinguish between these possibilities.  If the double adipocyte 
“knockouts” are phenotypically similar to AT1aRaP2 mice then AT2Rs likely have 
no effect.   If AngII promotes differentiation through the AT1aR and inhibits it 
through the AT2R, then AT1aRaP2 mice would display the greatest reduction in 
differentiation and AT1aR/AT2R double “knockouts” would be similar to floxed 
controls.  Conversely, if AngII promotes differentiation through both receptors, 
then AT1aR/AT2R mice would exhibit reduced adipocyte differentiation to a 
greater extent than that of AT1aRaP2 mice.  While floxed AT2R mice are not 
currently available, these would be the most useful tool to understanding the 
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possible roles of AT2Rs in adipocytes because the alternative options, using 
whole-body AT2R knockout mice or treating AT1aRaP2 mice with a 
pharmacologic AT2R antagonist may have indirect effects through other tissues.   
4.5.3 Dietary manipulations 
 In our studies, adipocyte-AT1aR deficiency was studied under several 
conditions including aged mice fed chow diet (with or without AngII infusion), lean 
mice, obese mice, hypercholesterolemic mice chronically fed Western diet, and 
hypercholesterolemic mice fed Western diet for 1 month (with or without AngII 
infusion).  The most striking effects on adipocyte size was observed in LF-fed 
mice and in chow-fed mice infused with AngII (Figure 4.1B), suggesting that the 
effects of adipocyte-AT1aR deficiency may be most relevant in lean mice with 
high AngII levels and future studies may employ the following models to achieve 
these conditions. 
4.5.3.1 Low salt diet 
 To maintain blood pressure under low-salt conditions, increased renin 
secretion increases AngII production, which then stimulates aldosterone 
secretion to induce sodium and water retention.  Feeding AT1aRaP2 mice a low 
salt diet represents a unique model where normal weight mice have a 
physiologically activated RAS, in contrast to AngII infusion which is an artificial 
means of increasing systemic AngII levels and has the added complication of 
potential weight loss.  A low-salt diet with similar fat content as normal chow may 
provide the necessary conditions for the maximum reduction of adipocyte 
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differentiation or other effects of adipocyte-AT1aR deficiency, which may then 
result in altered adipose tissue function.    
 A few studies have investigated the effects of high and low salt diets on 
adipose tissue.  Lima, et al. found that Wistar rats fed a high salt diet for 6 weeks 
have increased white adipose tissue mass compared to normal and low salt 
groups (83).  Interestingly, lipolysis assays performed on an adipocyte 
suspension found that basal and isoproterenol-induced lipolysis was stimulated 
in rats fed a high salt diet (83).  This is consistent with an inhibitory effect of AngII 
on lipolysis, because AngII levels are suppressed in high salt conditions so the 
inhibition of lipolysis would be curtailed.   Interestingly, a human study examining 
changes in adipose RAS components with low and high sodium diets found that 
expression of AGT, AT1R, and renin in subcutaneous adipose tissue were 
unchanged but ACE expression was actually upregulated with a high sodium diet 
(75).  These results suggest that circulating and tissue RAS components may be 
subject to differential regulation by sodium intake and adipose tissue itself can be 
directly influenced by sodium status.  Experiments using our model of adipocyte-
AT1aR deficiency would determine if the described changes in white adipose 
tissue due to sodium intake are due to direct effects of AngII at the adipocyte 
AT1aR. 
4.5.3.2 High carbohydrate diet 
 The LF and HF diets used in our studies are matched for protein content 
(20% kcal as protein) and are comprised of varying amounts of the same 
ingredients.  The HF diet contains roughly 12 times more lard than the LF to 
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increase the fat content and consequently, the LF diet contains 3.5 times more 
carbohydrates, which makes the LF diet arguably a high carbohydrate diet (70% 
kcal from carbohydrates).  From our studies, LF diet was the greatest stimulus for 
adipocyte hypertrophy in AT1aRaP2 mice, which may suggest a role for adipocyte 
AT1aRs in the response of adipose tissue to a high carbohydrate diet and other 
high carbohydrate diets may provide interesting models to further elucidate the 
roles this receptor.  AT1aR mRNA abundance in epididymal adipose tissue of 
rats was increased 50% by 14 days of high fructose diet (66% kcal from fructose) 
and increased 300% by 3 weeks of a high fructose, high salt diet; however 
adipose tissue mass or morphology was not characterized in this study (92).  
High sucrose diets also stimulate AT1aR expression specifically in rat epididymal 
adipose tissue but not in renal tissue (55).  If this drastic upregulation of receptor 
expression is in adipocytes and not other cell types, then studying adipocyte-
AT1aR deficiency under either of these dietary conditions may reveal further 
roles of adipocyte AT1aRs.   
4.5.3.3 Fasting or caloric restriction 
 Because the most dramatic effects of adipocyte-AT1aR deficiency on 
adipocyte hypertrophy were observed in lean mice, the purpose of adipocyte 
AT1aR may be to protect adipocyte differentiation in lean times.  Therefore, 
adipocyte-AT1aR deficient mice subjected to either acute fasting or chronic 
caloric restriction might lose more weight under these conditions compared to 
control mice, wherein AngII can temper the loss of adipose mass by promoting 
differentiation and/or possibly inhibiting lipolysis.  One study examining the 
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effects of an overnight fast in AT2R knockout mice found that adipose AT1aR 
mRNA abundance doubled in response to fasting (290).  Furthermore, AT2R 
knockout mice administered valsartan did indeed experience further reductions in 
adipocyte size and plasma NEFAs in response to fasting, supporting the idea of 
a protective role for AngII/AT1aR signaling in adipose under these conditions 
(290).  While this study was performed with an acute overnight fast, the 
protective role of AngII on adipose tissue may persist in the setting of prolonged 
undernutrition, such as caloric restriction.  The elevated fat mass observed in our 
studies of hyperlipidemic AT1aRaP2 mice infused with AngII suggest that this 
theoretical protective role of AngII may be specific to lean mice, and becomes 
dysregulated in hypercholesterolemic mice fed Western diet.  Alternatively, if 
AT1aRaP2 mice exposed to fasting or caloric restriction are also protected from 
the resulting reductions in body weight or fat mass, it would suggest that AngII 
acts through the adipocyte AT1aR to limit adipose tissue growth in some manner, 
though more studies would be required to determine if this is due to the 
established pro-differentiation effects of AngII.   
4.6 Clinical Implications 
 The primary role of AngII acting through adipocyte AT1aRs is to promote 
adipocyte differentiation, suggesting that AngII would have similar effects in 
humans as pharmacologic PPARγ ligands, by increasing the number of small, 
healthy adipocytes and potentially increasing insulin sensitivity.  This would imply 
that treatment with AT1R antagonists would result in adipocyte hypertrophy and 
potentially increased fat mass, as observed in AT1aRaP2 mice studied here.  
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However, clinical trials to date have found little evidence that ARBs influence 
body weight of patients taking them, especially when considering ARBs lacking 
PPARγ-agonizing properties that may represent AT1R-dependent effects more 
closely, such as losartan or valsartan (113, 132, 164, 236).  While two recent 
studies have found that losartan may reduce adiposity, measured by ultrasound 
(82) or waist circumference (7), the majority of studies have failed to find any 
effect of losartan on fat mass.  These clinical trials primarily include individuals 
with various combinations of metabolic risk factors in their study populations and 
thus limit their focus to overweight or obese patients.  Our data would suggest 
that the lack of an effect of ARB treatment on body weight may relate to the 
epigenetic suppression of adipocyte differentiation in the setting of obesity, which 
limits the effect of blocking the AT1aR on adipose tissue.  
 Adipocyte AT1Rs may play a more significant role in lean people, 
especially those with an activated RAS.  These conditions are met in patients 
with chronic heart failure and certain cancers known to have high circulating 
levels of AngII and experience weight loss (69).  Data from rodent models 
confirm that chronic high doses of AngII cause weight loss (34, 37, 47, 68).  
Weight loss and cachexia in chronic heart failure patients is associated with a 
worse prognosis, which is the basis of the “obesity paradox” whereby obese 
patients fare better (66).  Indeed, clinical trials indicate that administration of 
candesartan (201) or enalapril (10), though not losartan (200), mitigate weight 
loss in patients suffering from heart failure. These cachectic effects of AngII have 
been attributed to increased sympathetic nervous activity (77) or muscle atrophy 
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due to reduced insulin-like growth factor-1 (IGF-1) (34), however, reduced 
adiposity is a prominent feature of this phenotype and few have suggested a 
direct effect of AngII at adipocyte AT1Rs as a cause of weight loss.  Reduced 
adiposity may be due to a stimulatory effect of AngII on lipolysis (37, 68), 
however other animal studies indicate that AngII has, if anything, an anti-lipolytic 
effect on adipocytes (31, 96) and our own data show no effect of AngII on 
lipolysis.  Alternatively, AngII may not contribute to weight loss through the 
adipocyte AT1Rs, but may instead have a compensatory role to protect against 
too much weight loss and preserve the adipose depot by stimulating adipocyte 
differentiation.  In this case, the success of RAS blockade depends on the 
magnitude of pro-cachectic effects in some tissues weighed against the anti-
cachectic effects at adipocytes. 
4.7 Concluding remarks 
 Overall these studies suggest the primary role of AT1aRs on adipocytes is 
to promote adipocyte differentiation and increase or maintain the number of small 
adipocytes.  The consequences of AngII acting through adipocyte AT1aRs are 
most prominent in lean conditions and are absent in the setting of obesity.  
Future studies should identify the mechanisms through which AngII regulates 
adipocyte differentiation and explore non-obese models of RAS activation to fully 
understand the clinical significance of these findings.  Additionally, the impact of 
ARB administration on body weight and fat mass in patients suffering from 
cachexia should be studied in greater detail. 
 
 146 
 
 
Figure 4.1 Role of adipocyte AT1aR in adipocyte differentiation. A, AngII 
promotes adipocyte differentiation and the formation of small adipocytes through 
adipocyte AT1aRs. B, The effect of adipocyte AT1aR deficiency to promote 
adipocyte hypertrophy was greatest in lean mice and there was no effect in 
obese mice, which may be due to the amount or source of fat in the diets used 
across the various models. 
Copyright © Kelly Anne Putnam 2012 
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